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Abstract
Multiple non-animal-based test methods have never been formally validated. In order to use such new approach 
methods (NAMs) in a regulatory context, criteria to define their readiness are necessary. The field of developmental 
neurotoxicity (DNT) testing is used to exemplify the application of readiness criteria. The costs and number of untested 
chemicals are overwhelming for in vivo DNT testing. Thus, there is a need for inexpensive, high-throughput NAMs 
to obtain initial information on potential hazards, and to allow prioritization for further testing. A background on the 
regulatory and scientific status of DNT testing is provided showing different types of test readiness levels, depending on 
the intended use of data from NAMs. Readiness criteria, compiled during a stakeholder workshop that united scientists 
from academia, industry and regulatory authorities, are presented. An important step beyond the listing of criteria was 
the suggestion of a preliminary scoring scheme. On this basis a (semi)-quantitative analysis process was assembled on 
test readiness of 17 NAMs with respect to various uses (e.g., prioritization/screening, risk assessment). The scoring 
results suggest that several assays are currently at high readiness levels. Therefore, suggestions are made on how 
DNT NAMs may be assembled into an integrated approach to testing and assessment (IATA). In parallel, the testing 
state in these assays was compiled for more than 1000 compounds. Finally, a vision is presented on how further NAM 
development may be guided by knowledge of signaling pathways necessary for brain development, DNT pathophys-
iology, and relevant adverse outcome pathways (AOP).
This is an Open Access article distributed under the terms of the Creative Commons 
Attribution 4.0 International license (http://creativecommons.org/licenses/by/4.0/), 
which permits unrestricted use, distribution and reproduction in any medium, provi-
ded the original work is appropriately cited. 
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include the relevant tests for all biological pathways, processes 
and domains implicated in DNT.
1.2  Background on the use of existing in vivo 
test methods: Why are alternatives needed?
At present, there is no regulatory requirement for pesticides 
or other chemicals to be tested for DNT prior to registration. 
Instead, DNT testing can be triggered based on observed neuro-
toxic effects in repeat-dose in vivo animal testing, a known neu-
rotoxic mode of action, or a structure-activity alert, in Europe for 
pesticides, biocides and chemicals and in the US for pesticides. 
In these triggered cases, DNT testing is performed as an in vivo 
higher-tier test as there are no regulatory accepted alternative 
methods for this purpose. There are two regulatory guidelines 
for DNT testing, both in rodents: OECD TG 426 (Developmen-
tal Neurotoxicity Study), which is an update of the 1998 US EPA 
DNT Guideline, and OECD TG 443 (Extended One-Generation. 
Reproductive Toxicity Study, DNT cohort). Both require neuro-
behavioral evaluation of cognitive, sensory and motor function, 
accompanied by histopathological and morphometric evaluation 
of the brain, but they do not provide detailed guidance on the use 
of specific behavioral tests, leaving flexibility in the study design 
and in the interpretation of the results obtained. Moreover, TG 
426 and TG 443 present a number of challenges and limitations 
(Claudio et al., 2000; Crofton et al., 2004, 2011; Tsuji and Crof-
ton, 2012; Smirnova et al., 2014), including:
1. They are time- and resource-consuming, low-throughput as-
says.
2. A large number of animals is required.
3. Differences in techniques and measures, especially for behav-
ioral endpoints, can make it difficult to compare data between 
studies.
4. Implementation of the DNT guideline methods in contract 
laboratories has resulted in datasets with high variability and 
low reproducibility, even for positive controls.
5. Measured pathological and behavioral endpoints provide no 
mechanistic understanding of the underlying effects. 
6. The currently required tests do not capture important complex 
endpoints of relevance for humans, for example higher cogni-
tive functions.
7. The predictivity for protection of the human brain is based on 
a very limited number of chemicals, and rodent studies may 
not reflect some toxicodynamic processes in humans, leading 
in some cases to uncertainty about the relevance of animal 
outcomes for human DNT. 
In reality, TG 426 and 443 are seldom conducted. Studies are 
currently available for only a relatively limited number of 
substances (about 120) (van Thriel et al., 2012; Kadereit et 
al., 2012; Crofton et al., 2012). Therefore, the urgent aim is to 
develop alternative test methods as part of a test strategy that 
1  Introduction 
1.1  Objectives of the meeting 
and follow-up activities
A recent OECD/European Food Safety Authority (EFSA) 
workshop on the use of non-animal test methods for regulato-
ry purposes in the area of developmental neurotoxicity (DNT) 
proposed to develop a standardized in vitro testing battery that 
could be used to generate data on the toxic effects of chemicals 
on the developing nervous system. It was recognized that there is 
an urgent need for a new alternative testing strategy that supports 
regulatory decisions with a focus on two specific aims: the first is 
to use existing alternative test methods to support screening and 
prioritization of chemicals for future testing, the second aim is 
to generate data that aid in guiding risk management decisions. 
The workshop concluded that the next task was to establish per-
formance standards and develop a guidance document for an in 
vitro DNT testing battery (Fritsche et al., 2017a). 
The International Stakeholder Network (ISTNET) on DNT 
testing is a collaborative effort of groups from academia, in-
dustry and regulatory bodies that aims to align the development 
of alternative (non-animal) testing methods with the needs of 
regulatory decision-making. A first meeting in Zurich in January 
2014 explored the potential of applying the adverse outcome 
pathway (AOP) framework to promote test system development 
according to regulatory needs, and to assemble predictive inte-
grated testing strategies (ITS) for DNT (Bal-Price et al., 2015a). 
With the outcome of the OECD/EFSA workshop in mind, a 
second ISTNET Workshop took place in Konstanz in January 
2017, focused on practical aspects of such pathway-based test-
ing, and in particular on performance standards that should be 
applied to alternative DNT tests. The immediate objectives of 
the meeting and its follow-up activities were:
1. Define criteria for evaluation for readiness of a given test 
method.
2. Evaluate to what extent these criteria are fulfilled.
For the second objective, proof-of-principle examples are given 
here on how an evaluation may be performed; as information 
only historical, published information was used. Therefore, mid-
term objectives were defined to continue this process:
A. Establish a standardized evaluation system for assay readi-
ness.
B. Define a list of suitable test methods based on these criteria.
C. Establish criteria for a battery of tests for use in a DNT IATA 
based on readiness scores.
D. Build an IATA for initial chemical screening and prioritiza-
tion.
The long-term goal is to define a battery of alternative tests 
based on developmental ontologies (in contrast to the mid-term 
goal of performance-based test definition). Such a battery would 
Abbreviations
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is the need for testing large numbers of chemicals for their DNT 
potential (Crofton et al., 2012; EFSA, 2013; Bal-Price et al., 
2015a; Fritsche et al., 2017a).
1.3  Making alternative methodologies for DNT 
testing acceptable for regulatory purposes 
Reliability and human relevance are the two critical require-
ments that have to be addressed for regulatory acceptance of 
alternative test methods. The OECD Adverse Outcome Pathway 
(AOP) framework (OECD, 2013; Ankley et al., 2010; Bal-Price 
et al., 2015b; Leist et al., 2017; Terron et al., 2018) is useful 
in defining the human relevance of data from individual test 
systems as it takes all available data, including human epidemi-
ology and human in vitro data, into consideration. Moreover, it 
allows development of quantitation and threshold models on the 
basis of quantified key events (KE) in an established AOP. 
The assessment of the readiness and reliability of alternative 
DNT methods for regulatory purposes is currently lagging be-
hind the extremely rapid development of new technologies (e.g., 
induced pluripotent stem cells, 3D cell co-cultures and organ-
oids, high-content omics measurements, bioinformatics tools, 
etc.) (Leist et al., 2008a, 2014; Marx et al., 2016; Rovida et al., 
2015; Smirnova et al., 2016). This is unfortunate, since more 
guidance on how to ensure reliability of the available and new in 
vitro DNT assays would help researchers in designing, conduct-
ing, and reporting studies. It would also encourage regulators to 
take NAMs into account. 
Therefore, the major focus of this workshop report is to pro-
vide a set of readiness criteria that potentially could be accept-
able to both regulators and test developers. Moreover, examples 
are given on how a readiness evaluation of existing in vitro 
DNT assays could be applied to various regulatory applications. 
Preliminary scoring by workshop participants of over a dozen 
methods demonstrates that the field of DNT-NAM is ready to 
support some regulatory decisions. The readiness criteria will 
also be helpful to harmonize development of new in vitro tests 
and to ensure their reliability and relevance.
In addition to data reliability and relevance evaluation, both 
researchers and regulators will need guidance on data integration 
from a battery of alternative DNT assays (Behl et al., 2015) in 
the form of ITS and defined approaches (DA) (OECD, 2016c). 
This enables a tiered approach, spanning the spectrum from 
hazard identification/characterization as an input to quantitative 
risk assessment, aiding the application of human health-related 
decisions based on data coming from alternative approaches. 
Outstanding regulatory challenges for accepting alternative 
DNT test data are similar for most alternative methods and in-
clude uncertainty due to genetic background, cell type and to-
pography, life-stage, and exposure temporality in dose-response 
modeling (Hartung et al., 2017a,b). Some of these issues are 
addressed in the AOP framework (Bal-Price and Meek, 2017; 
Leist et al., 2017; Terron et al., 2018), which will thus help in 
their resolution.
Current hazard identification processes based on in vitro tests 
accepted by regulatory agencies rely on molecular and cellular 
KEs within AOPs. Here, the most prominent example is the ap-
plication of a testing battery based on KEs identified in the AOP 
at least can identify DNT alerts and guide prioritization at a 
lower-tier level.
A recent review, focused on pesticide active substances, was 
presented at the DNT OECD/EFSA workshop in Brussels (Frit-
sche et al., 2017a) by the German Federal Institute for Risk As-
sessment (BfR). To date, DNT studies have been conducted on 
only 35 of the 485 pesticide active substances currently approved 
in the EU. Of these 35, 19 displayed positive in vivo evidence of 
DNT. It should be noted that a large proportion of these 485 pes-
ticide active substances were classified as adult neurotoxicants 
(Grandjean and Landrigan, 2006). It is unknown whether a sim-
ilarly high rate (> 50%) of positive DNT results would be seen 
for other classes of chemicals that are not enriched in neurotox-
icants. Moreover, the DNT testing led to health-based guideline 
reference values for only 2 of these 19 positive compounds. 
An alternative analysis of DNT studies by the USEPA in 2010 
demonstrated that of 72 DNT studies, 15 were used to determine 
the point of departure for one or more risk assessment scenarios, 
and an additional 13 were determined to have the potential for 
use as a point of departure for future risk assessments (Raffaele 
et al., 2010). These assessments are limited to a small number of 
chemicals that in no way represents the known chemical space of 
environmental chemicals (Richard et al., 2016). Thus, to clarify 
the need for DNT testing for regulatory purposes, experimental 
evidence on the potential for DNT hazard for many more chem-
icals is required. However, for this purpose the tests need to be 
more time- and cost-effective. 
The sensitivity of the currently used in vivo DNT test has been 
questioned (Claudio et al., 2000; Vorhees and Makris, 2015). 
Some of the issues may be due to toxicodynamics, others may be 
explained by different toxicokinetics among species (metabolic 
activity or placental transfer in animals compared to humans as 
exemplified earlier (reviewed in Aschner et al., 2017)). The issue 
of sensitivity is, for example, evident regarding the predictivity 
value of the rat DNT assay for the evaluation of chemicals acting 
on the hypothalamic-thyroid axis. Despite the human evidence 
linking developmental hypothyroxinemia with changes in brain 
development in children (Haddow et al., 1999; Henrichs et al., 
2010), several DNT studies investigating rodent offspring from 
hypothyroid/hypothyroxinemic dams have shown that adverse 
behavioral outcomes were not always present (York et al., 2005). 
Although multiple explanations may clarify this issue and should 
be taken into account (e.g., severity of the effect in the dams, 
limited milk transfer of the compound, neurobehavioral assess-
ment methods not suited for the detection of subtle effects in 
the brain, presence of compensatory mechanisms), it is evident 
that design, conduct and interpretation of in vivo DNT studies 
are complicated. Species differences of developing brain cells in 
response to thyroid hormones have recently been reported also 
on the level of pharmacodynamics (Dach et al., 2017).
Due to these issues, the US EPA Office of Pesticide Programs 
(OPP) suggested to include alternative approaches in the testing 
paradigm to improve DNT hazard identification in the context of 
analyzing DNT in vivo studies for 72 pesticide active substances 
(Raffaele et al., 2010).
Another reason regulatory bodies and authorities support the 
development of alternative medium- to high-throughput assays 
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synaptogenesis” or “decreased neuronal network function” (Bal-
Price et al., 2015b; Sachana et al., 2016), see also AOP-Wiki1. 
However, as the number of available DNT AOPs is small, basic 
clinical as well as toxicological sciences may inform us on rele-
vant and measurable neurodevelopmental KEs, as summarized in 
Fritsche et al. (2015) and Fritsche (2017b). 
Examples from the toxicological side include methylmer-
cury-induced inhibition of neural cell migration (Bal-Price et al., 
2015b; Moors et al., 2007), arsenic-induced inhibition of neural 
progenitor cell (NPC) proliferation (Chattopadhyay et al., 2002), 
valproic acid-induced inhibition of neural crest cell migration 
(Zimmer et al., 2012), or neuronal differentiation (Foti et al., 
2013; Balmer et al., 2012, 2014; Waldmann et al., 2014, 2017). 
For these examples, the compounds’ modes of action (MoAs) 
are being elucidated (Bal-Price et al., 2015b). 
Knowledge from clinical research on neurodevelopmental dis-
orders with genetic alterations as basis for disease are also help-
ful in determining human-relevant, cell-based endpoints. Here, 
for example, diverse receptor tyrosine kinase (RTK) mutations, 
leading to activation of protein kinase B (AKT, PKB), can cause 
for skin sensitization (OECD 2016b; Delrue et al., 2016; Adel-
eye et al., 2015; Urbisch et al., 2015). Transferring this concept 
to DNT, where currently only a few relevant AOPs are available, 
and where many more pathways might underlie toxicity for the 
developing brain (Bal-Price et al., 2015b, 2017; Bal-Price and 
Meek, 2017), a similar procedure is not yet feasible. Therefore, 
in vitro assays anchored to key cellular neurodevelopmental pro-
cesses should guide the development of an alternative DNT test-
ing battery (Fritsche et al., 2017a; Aschner et al., 2017; Schmidt 
et al., 2017; Bal-Price et al., 2010, 2012; Crofton et al., 2011). 
Since 2005, an international community used the CAAT Tox-
Smart DNT meetings as a basis to propose alternative approaches 
for DNT evaluation (Lein et al., 2005; Coecke et al., 2007; Crofton 
et al., 2011; Bal-Price et al., 2012, 2015a; Smirnova, 2014; Leist 
et al., 2012). The above-mentioned processes-based alternative 
DNT testing strategy is a result of this ongoing exchange between 
basic researchers and regulatory scientists. Such cellular KEs are 
intermediate to late KEs in an AOP, and examples from existing 
DNT AOPs include, e.g., “impaired neuronal differentiation” 
(Bal-Price et al., 2015b; Bal-Price and Meek, 2017), “decreased 
1 https://aopwiki.org/
Fig. 1: Fundamental neurodevelopmental processes relevant for DNT
Several neurodevelopmental processes are essential for nervous system development. These processes, known from in vivo studies, can 
be relatively faithfully modelled in vitro. It is assumed that DNT toxicants exert their toxicity by disturbing at least one of these processes. 
Therefore, disturbances of the processes depicted here in blue boxes are KEs of AOPs relevant for DNT. The figure gives a short overview 
of nervous system development from simple precursors (left side) to complex functional tissue (with cell-cell interactions) on the right side. 
For a DNT test battery all these biological processes should be covered by one or more test methods. 
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211) provides a template for assay annotations of non-guide-
line in vitro methods (OECD, 2014b). GD 211 harmonizes the 
manner in which non-guideline in vitro methods are described, 
and thereby facilitates assessment (by the regulator) of the reli-
ability and relevance of the produced data. The US EPA Office 
of Pesticide Programs recommends following this guidance to 
describe non-guideline in vitro methods for acute toxicity (EPA, 
2016). According to this guidance (OECD, 2014b), the method 
description should include purpose and scope of the assay, meth-
od components including protocol and reference chemicals, the 
stage of development of the assay, the quality/acceptance crite-
ria, data interpretation and prediction model(s), and performance 
metrics including sensitivity and predictivity (i.e., proportion of 
false negatives for positive controls, and of false positives for 
negative controls).
A further important document is the guidance document on 
Good In vitro Method Practices (GIVIMP) for the development 
and implementation of in vitro methods for regulatory use in hu-
man safety assessment (expected release: 2018). This guidance 
(draft version OECD, 2017a) will be of central importance in 
regulatory acceptance of the proposed DNT alternative methods. 
It describes the scientific, technical and quality practices needed 
at all stages between in vitro method development to implemen-
tation for regulatory use. These include roles and responsibilities 
(of developers, component providers and users), quality consid-
erations, facilities, apparatus, material and reagents, test systems, 
test and reference/control items, standard operating procedures, 
method performance, and reporting of the results. The GIVIMP 
document has been written for various users, including GLP test 
facilities but also research laboratories developing new in vitro 
methods for regulatory purposes. In the latter case, full compli-
ance with GIVIMP may not be realistic, but compliance with 
as many as possible of the “good practices” will facilitate the 
acceptance and routine use of the in vitro method in a regulatory 
environment. 
It is understandable that the completeness of the information 
recommended in the OECD guidance will vary, because the level 
of development of the DNT alternative methods is different, and 
this in turn impacts the use of the methods for different regulato-
ry applications. However, in all cases, the suggested framework 
aims to cover some information on 1) a test method definition 
(including purpose, scientific principle, metabolic competence, 
quality control criteria, technical limitations and strengths); 2) 
test method performance (robustness, reference chemicals, per-
formance measures/predictive capacity); 3) data interpretation; 
4) potential applications; and 5) supporting information avail-
able in the existing databases (e.g., DataBase on ALternative 
Methods DB-ALM of EURL-ECVAM2). 
In this context, the consideration of “applicability domains” 
takes an important and often underestimated role. The test meth-
od must be considered like a tool. And like all tools, it has a 
proper domain of application (e.g., scissors to cut paper), bor-
derline domains of application that require case-by-case evalu-
ations (e.g., use of scissors to punch holes or to open a bottle), 
a variety of morphological disturbances in humans that are based 
on deregulation of brain cell proliferation and apoptosis (re-
viewed in Hevner, 2015). Also, aberrant expression of the brain 
derived neurotrophic factor (BDNF) and its dependent mole-
cules, extracellular signal-regulated kinase (ERK) and cAMP 
responsive element binding protein (CREB), have been linked 
to numerous psychiatric disorders, including autism spectrum 
disorders, mood disorders and schizophrenia. Cellular functions 
controlled by these pathways are numerous, including brain cell 
proliferation, dendritogenesis, and synaptogenesis (reviewed in 
Ehrlich and Josselyn, 2016). These are only examples; a more 
detailed compilation of relevant neurodevelopmental pathways 
and cellular functions can be found in Fritsche et al. (2017b). 
Modelling these key neurodevelopmental processes, from cell 
division up to neuronal network formation (Fig. 1), in a NAM 
testing battery will yield information on relative sensitivities of 
the processes to chemicals. For a small subset of endpoints, the 
principle of detecting the most sensitive process, and extrapolat-
ing from its disturbance in vitro to an in vivo hazard, has been 
exemplified in Baumann et al. (2016). Thus, information from 
batteries of tests run in parallel will not only serve as readouts for 
DNT hazard but will also inform future assay development and 
design of AOPs. While focusing on all these positive aspects, it 
will be important to bear in mind that fundamental issues of in 
vitro assays need to be kept in mind: for instance, the metabolic 
capacities that may differ from the in vivo situation, the interac-
tion of different cell types that may largely affect their response 
pattern (Gantner et al., 1996), and issues of biological barriers 
(Leist et al., 2014; Kadereit et al., 2012; Aschner et al., 2017).
2  General guidance of quality and performance  
standards
2.1  OECD guidance on test descriptions  
and readiness
The rationale for alternative DNT testing is given by the con-
sensus between academic, industry and regulatory scientists that 
chemicals with the potential to trigger DNT should be properly 
identified and that the current testing paradigm, based on in vivo 
studies, does not satisfy this need (Fritsche et al., 2017a). For 
moving alternative DNT tests into action, scientists should focus 
on defining and applying test specifications (Leist et al., 2010, 
2012) and validation paradigms to evaluate their readiness and 
draw a roadmap for their application in a regulatory context. 
The meaning of the term readiness varies strongly between 
different interest groups (Fig. 2). For instance, an academic re-
searcher uses a cellular model system to investigate pathways of 
cellular functions and needs a reliable model that mimics human 
effects. However, this is only the starting point for the work of 
the test system developer. 
Regulatory acceptance of individual tests will be facilitated 
by adherence to international regulatory consensus guidance. 
For instance, the OECD Guidance Document No. 211 (GD 
2 https://ecvam-dbalm.jrc.ec.europa.eu/
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multiple information sources (OECD, 2016b). A DA can be built 
in various ways and may take the form of a sequential testing 
strategy (STS) or an ITS. The fixed data interpretation procedure 
is then used to interpret data generated with a defined set of alter-
native methods that can either be used on its own or together with 
other methods and existing information within an IATA (OECD, 
2016a). In this case, the template for data reporting of individual 
information sources used in a DA that was published in an OECD 
guidance (OECD, 2016b) will ensure a transparent and accurate 
documentation of the methods used within a DA. Within such a 
DA, information has to be documented properly to ensure trans-
parency of the methods used. The description should include the 
chemical and/or biological mechanism addressed by the meth-
ods and provide some indications of the plausible linkage of the 
modelled mechanisms or neurodevelopmental processes to the 
apical endpoint being predicted. Known scientific confidence and 
limitations of methods should also be reported, including a com-
parison to existing similar non-testing or testing methods.
Principle 1 aims to ensure clarity in the endpoint addressed, 
by defining it. From this perspective, a relationship between the 
combination of the alternative test methods’ endpoint(s) and 
the biological phenomena of interest should be explored. The 
limitations (e.g., inability to determine DNT effects secondary 
to systemic effects like hormonal imbalance) are to be clearly 
identified. The scientific validation of the testing strategy should 
be based on a mechanistic ground with the assumption that a de-
rangement of fundamental processes in neurodevelopment will 
lead to an adverse effect.
and applications that are physically possible, but usually lead 
to non-satisfactory results (e.g., use of scissors to open a can or 
to turn screws). For DNT test methods, several dimensions of 
“applicability domains” are important. The three most import-
ant ones are: 
(i)  the type of chemicals to be tested;
(ii)  the type of mechanisms explored; 
(iii)  the type of (regulatory) questions addressed. 
Thus, a given method may be more ready for certain applications 
and less ready for others!
2.2  Principles for evaluation of the readiness of 
test strategies based on multiple test methods
A systematic approach to building a test battery should first de-
termine the readiness of individual alternative DNT methods. A 
general set of readiness criteria has been proposed by OECD 
(2014b), and these have been clustered in four categories (Tab. 
1). Such guidance has been considered here in compiling spe-
cific readiness criteria for DNT test methods, and in devising a 
preliminary scoring system to obtain indications on the readiness 
status of various published tests (see chapters below). Currently, 
none of the proposed DNT alternative methods are stand-alone 
methods, thus a battery of the assays that capture essential infor-
mation across neurodevelopmental processes and developmental 
timing is considered important for a comprehensive hazard as-
sessment. Here, we discuss briefly the evaluation of ITS. 
The evaluation of ITS could be based on the principles devel-
oped for the reporting of DAs to testing and assessment based on 
Fig. 2: Different perspectives of DNT alternative methods’ readiness evaluation
In the discussion on “test readiness” it is important to note that different fields and stakeholders have their own perspective. Three of  
these perspectives are outlined. For each of them, examples for increasing grades of readiness and final goals are given. These 
perspectives are interdependent to some degree: (i) a test that is 100% ready for an academic investigator in basic science can form  
the starting point for a toxicological test developer; (ii) a test that is considered ready by the test developer may be at the start of  
regulatory readiness, e.g., with respect to formal validation; and (iii) a test that is at the highest regulatory readiness level (OECD TG)  
may provide a starting point for academic researchers who want to unravel key mechanisms and pathways that are essential and  
that biologically explain the test read outs. 
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dictions or only for specific pathways or mechanisms of action. 
Additionally, the level of confidence (reliability of prediction) 
associated with the application of the testing strategy to different 
chemicals is needed. It is relevant to include as many chemicals 
as feasible as the determination of the applicability domain is 
expected to be correlated with the number and diversity of chem-
icals tested. More importantly, this principle aims to capture the 
variability of the data produced by the alternative methods as 
well as the variability of the output data (i.e., from the DA) asso-
ciated with the reference data (e.g., animal or human DNT data) 
used as benchmark data. In other words, the prediction of a DA 
aims to capture the variability and uncertainty of the alternative 
approach and the reliability of the gold standard data by applying 
appropriate statistical concepts and qualitative approaches.
The application of these criteria and principles helps to estab-
lish the overall relevance of the alternative methods and of the 
testing strategy. 
3  Evaluation of in vitro DNT assays against  
defined readiness criteria
3.1  Compilation of readiness criteria
The development and application of in vitro test methods is 
driven by various stakeholders: basic academic researchers, test 
developers in industry and public institutions, and regulatory de-
cision makers. As shown and discussed in Figure 2, these three 
Principle 2 aims to ensure clarity in the purpose for which the 
combination of the alternative methods is proposed. Considering 
that a test method should fit for a specific purpose, the problem 
formulation should be defined at the beginning of the process. 
This would not only include the regulatory purpose, i.e., screen-
ing and prioritization vs. single chemical hazard identification, 
but it would also specify the target performance values (predic-
tive capacity required).
Principle 3 intends to provide transparency on the rationale 
used for applying DAs. The rationale may be based on an exist-
ing AOP or network of AOPs or other mechanistic information 
relevant to the endpoint. In the case of DNT, due to the lim-
ited number of available AOPs, mechanistic information de-
rived from studies exploring disturbance of brain development 
processes by well-established DNT compounds can form the 
rationale for constructing a DNT testing strategy that relies on 
alternative methods (Fritsche, 2017a,b).
Principle 4 deals with data generated by the different infor-
mation sources and how it is used within the DA to derive a 
prediction/assessment and aims to provide transparency on 
this aspect. The description should ideally include a schematic 
representation (e.g., flowchart or decision tree) to illustrate the 
procedure. The approach followed to provide prediction needs to 
be documented and understandable by the regulators.
Principle 5 allows the capture of the sources of uncertainty 
in predictions. Of particular interest would be to define if the 
proposed DNT testing strategy is reliable only for positive pre-
Tab. 1: Example for ranking parameters for in vitro methods to detect chemicals that disturb the thyroid hormone axis  
Ranking parameters were established by OECD for thyroid-disrupting chemicals to determine the readiness of tests for validation (OECD, 
2014a). The criteria in Category 1 are considered of highest priority. Each criterion within this category is considered to have equal weight, 
and all are essential to demonstrate the readiness of the assay. For instance, the assessment of the biological plausibility is considered very 
important in defining readiness of the method for validation. However, criteria in this category are hard to quantify. Moreover, many DNT tests 
cover multiple mechanisms and processes with varying levels of plausibility and data on their in vivo relationship. Thus, the practical value 
of such criteria for DNT methods needs to be considered case-by-case. The criteria for Category 2 are better defined and quantifiable. They 
relate to the evaluation of reliability and efficacy of the method. Sufficient positive and negative compounds should be included to assess 
specificity and sensitivity, and focus should be given to the robustness of the assay. Regarding Category 3, the criteria are also relevant 
to assay performance evaluation. However, the particular performance issues described under this category are considered to be of less 
significance during initial phases of test development and evaluation. Category 4 contains criteria for the methods that are considered good 
to meet in order to gain broad acceptance. 
CATEGORY 1 CATEGORY 2 
Initial high priority considerations Method performance considerations
Biological plausibility Within-laboratory reproducibility 
Extrapolation to humans or broadly applicable across  Between-laboratory reproducibility 
vertebrates/phyla Assay variability 
Availability of resources Accuracy 
Reference chemicals Assay specificity/assay sensitivity 
CATEGORY 3 CATEGORY 4 
Technical capability Other practical considerations
Dynamic range/concentration test range Technological transferability/proprietary elements 
Detection/adjustment of confounding factor and/or incorrect/ Transparency of the method 
inconclusive measurements and/or other bias Documentation of development and utility of the method 
Response characterization  
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they been clearly and explicitly described? Are examples for 
normal performance and morphology given? Are there examples 
for alerts?” Finally, examples of the type of information required 
are given. In the chosen example: “E.g., cell density on a specif-
ic day of differentiation could be a critical step; wrong, strange 
morphology of cells could be an alert”. In this way, a compro-
mise was reached between length (and clarity) of the document, 
and the information needed to perform a readiness evaluation 
(Tab. 2).
Our criteria list is meant to provide an easy-to-use tool for 
test developers and users in order to provide a quick and fast 
overview for them to judge how far the method is developed 
and what important points need to be addressed. Moreover, the 
semi-quantitative or quantitative scoring may help regulators to 
identify the strengths and weaknesses of a given test method. 
This could help them to decide to what extent the data generated 
by a given test method could be used. Notably, the tool may also 
be useful to identify and exclude data from non-ready methods 
from regulatory use or to prevent scientifically unsound data 
from creating anxiety in the general public. 
groups may have different points of view regarding the readiness 
of a test method. Moreover, readiness depends on the application 
of a method, on the field of toxicology in question (here DNT), 
and on the quality of animal experiments in the given field 
(Hartung and Leist, 2008). To take all this into account, a 2-step 
consensus process has been organized to establish a practical set 
of readiness criteria. They were first suggested and discussed 
during a workshop with different stakeholders and then assem-
bled for this report by a working group. A third step (described 
below) involved testing of the applicability of the criteria for 
actual scoring.
The criteria were clustered into 13 groups, e.g., concerning 
the test system, the prediction model, or the applicability for 
screening. For each of the criteria, a short heading was defined 
(e.g., critical components of the cell system). Then, the criterion 
was described in more detail. To do this, specifying or guiding 
questions often have been defined that need to be answered to 
provide information on the respective criterion. For instance, 
for the “critical components of the cell system”, this is “Have 
critical components and handling steps been identified and have 
Tab. 2: Performance criteria to define the readiness of test methods for hazard evaluation 
This set of criteria was developed with the needs of toxicological test developers in mind. It should help them to prepare their assay for 
priority screening as well as for incorporation in an ITS. In the first column, the criteria are listed in their short form, the second column gives 
a definition or short description of each criterion (with some supporting and guiding questions), and the third column provides examples  
or further explanations for each of the criteria. The fourth column gives the maximum score that can be reached. There are 13 main 
categories of criteria, each with different numbers of sub-items. Within each main category, the sub-item can be scored for a readiness 
evaluation, and the sum of these scores results in the score for the main category. The fourth column indicates the maximum score that can 
be given for each category. The main criteria can be assigned to three different phases of test method development (Phase I in pale blue, 
phase II in medium blue, phase III in dark blue, Fig. 3). The topics printed in italics (e.g., 1j, 3a, 3c, 4d, 5d, 5e, 5i) may not apply to each test 
method. If they do not apply, the score is automatically set to 1 for these sub-items. 
Abbreviations: AOP, adverse outcome pathway; BMCL, benchmark concentration lower bound; CRO, contract research organization;  
EC, endpoint-specific controls; KE, key event; MIE, molecular initiating event; NC, negative controls; PC, positive controls; S/N, signal noise 
ratio; SOP, standard operation procedure; STR, short tandem repeat; UC, unspecific controls.
Criteria Description Examples / Why is it important Max. score
1 Test system
1a  
What is modelled 
 
1b  
Relevance 
 
 
 
 
1c  
System uncertainties 
and human correlate 
(HC) 
 
 
 
10
1 
 
 
1 
 
 
 
 
 
1 
 
 
 
 
 
 
Is there a clear rationale given for what 
target organ/tissue relevant for human 
poisoning/pathology the test system should 
reflect?
Is the chosen test system known to be a 
key component in pathogenesis, or why 
is it thought to reflect a key component, 
mechanism or tissue? 
 
 
(i) Is there a discussion on where the test 
system differs from the mimicked human 
tissue, and which gaps of analogy need to 
be considered?  
(ii) Do toxicant-altered genes (or other 
biomarkers) correspond to changes in 
mimicked human tissue (after poisoning or in 
relevant pathologies)?
Note: here scoring not for “test method”
Here: Question is not of relevance but whether 
there is documentation and a rationale at all.  
 
Here: Is the tissue/organ modelled important 
for regulatory toxicology or biomedical 
research purposes? Is evidence given for 
the relevance of the model by morphological 
comparison, gene expression or functional 
criteria? Are all/sufficient cell types included  
in the model?
(i) E.g., a differentiated cell or a cell line (such 
as HepG2) does not necessarily reflect all 
features of the corresponding in vivo tissue/
conditions.  
(ii) This is an additional measure to increase 
confidence in the test – not mandatory, but 
helpful.  
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Criteria Description Examples / Why is it important Max. score
1d  
Definition of cells 
 
 
 
1e  
Cell composition 
 
 
 
 
 
1f  
Cellular environment 
 
 
 
1g  
Biological consistency 
 
 
 
 
 
 
 
 
 
 
1h  
Critical components 
 
 
1i  
Cell stability 
 
 
1j  
Transgenic cells 
 
 
2 Exposure scheme
2a  
Description 
 
2b  
Unique identity 
1 
 
 
 
 
1 
 
 
 
 
 
 
1 
 
 
 
 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
 
 
1 
 
 
 
3
1 
 
 
1 
 
Is the test system sufficiently characterized 
(source, multiple positive and negative 
markers for cell identity, number, quality, 
composition, differentiation state, viability, 
usual morphology, basic function, basic 
reaction to stimuli, STR analysis)?
For multi-component systems: information 
on all cellular subpopulations. What is the 
percentage of contaminating cells or in 
co-cultures what is the percentage of all 
subpopulations.  
 
 
Information on structuring components 
of the test system: coating, scaffolds, 
matrix description, medium (supplements), 
microfluidic effects, supportive cells, 
dimensions and positioning/handling of 3D 
constructs, etc.
(i) Has the variation of the test system  
been assessed, have influencing factors 
been identified?  
(ii) Have acceptance criteria and 
performance standards for the test system 
been defined (different from the test!)? 
 
 
 
 
 
 
Have critical components and handling  
steps been identified and described?  
Are examples for normal performance  
and morphology given? Are there examples 
for alerts?
Stability proven over multiple doublings; 
genetic stability shown; pluripotency/
multipotency (for stem cells) shown, cell 
identity shown. 
Transgene characterized (source, sequence, 
regulation); insertion characterized;  
stability of function shown and quantified; 
cell identity and function related to wildtype; 
clonality documented.
Complete, detailed, unambiguous 
 
 
Tests with multiple variants need to define 
very transparently, which variant the data 
comes from.
This is especially important for cells that  
have to be produced regularly, e.g.,  
by differentiation or primary cell isolation.  
 
 
This is important for the test endpoints as 
it could be that only one cell type may be 
affected by a toxicant. For primary cells: 
Have cells from different sources (suppliers) 
been tested (e.g., hepatocytes from different 
suppliers may differ in purity and quality)?  
For routine use it would be beneficial to have 
pre-set acceptance criteria for each cell type.
This means a very detailed description of 
the culture conditions, including temporal 
and spatial aspects. Cell differentiation and 
response (quality, quantity, kinetics) may 
depend on multiple external factors and on  
the 3D arrangement.
(i) E.g., do medium supplements have an 
influence on the outcome of the cells, such as 
batch effects of FCS or serum replacement 
additives?  
(ii) E.g., a range of marker expression levels, 
of biological function (proliferation, protein 
production, etc.), of structural features (cell 
number, organoid size, etc.). For cell lines: 
What is the optimum passage number for 
cells?  
For routine use it would be beneficial to have 
pre-set acceptance criteria for the whole 
model/test system.
E.g., cell density on a specific day of 
differentiation could be a critical step; wrong, 
strange morphology of cells could be an alert.  
For routine use it would be beneficial to have 
pre-set acceptance criteria.
For stem cells, stability needs to be shown 
over many passages (≥ 10). For primary cells, 
stability and identity of supply needs to be 
shown. Stability of function (e.g., xenobiotic 
metabolism) needs to be shown. 
 
 
 
 
Medium changes, re-additions, coating, 
treatment period and timing, incubation 
conditions (temperature, humidity, gassing, 
etc.)
E.g., from which cell type/clone; which time; 
which plate format; which medium additives, 
etc.
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Criteria Description Examples / Why is it important Max. score
2c  
Graphical scheme
3 Documentation / 
SOP
3a  
Availability 
 
 
 
3b  
Stage of development
3c  
For CRO tests 
 
3d  
Test components
 
 
 
3e  
Stocks
4 Main endpoint(s) 
4a  
Biological relevance
4b  
Toxicological 
relevance
4c  
Analytical methods
4d  
Multiple endpoints
5 Cytotoxicity 
5a  
Cytotoxicity within test 
 
 
 
 
 
5b  
Subpopulation effects 
 
5c  
Specificity (compared 
to cytotoxicity)
5d  
Timing within test 
 
1 
5 
1 
 
 
 
 
1 
1 
 
 
1 
 
 
 
1 
4 
1 
1 
 
1 
1 
5
1 
 
 
 
 
 
 
0.5 
 
 
0.5 
 
0.5 
 
 
Complete sequence of events including 
endpoint assessment
 
Method description for test system, test 
procedure, analytical endpoints and 
prediction model; public availability of SOP 
(data bank or test developer upon request) 
 
Version history; updated 
Are full performance standards and 
corresponding data delivered by the CRO 
along with test data (in case SOP details  
are not disclosed)
Documented and available (receipt, storage, 
handling and disposal documents); quality 
criteria and checking procedure established 
 
Procedure for preparation, storage and 
quality control of stocks established
 
Is there a rationale given why the test 
endpoint is relevant to adverse outcomes?
Are toxicants (≥ 3) known to affect  
the endpoint 
Methods defined, rationale given; positive 
controls and acceptability criteria
Are all endpoints and their relation to one 
another (priority, preference) defined?
Cytotoxicity is preferentially determined 
within same test compartment as the major 
endpoint; second choice is under same 
conditions in parallel 
 
 
 
Are subpopulations detected by measure 
for cytotoxicity or proliferation? Are minor 
changes detected? Has sensitivity been 
shown?
A measure needs to be established to 
distinguish a specific/functional endpoint 
from cytotoxicity
For repeated/prolonged dosing, early death 
and compensatory growth need to be 
considered. 
Supports clarity and data assignment to test 
variants
 
Normal scientific publications are usually not 
sufficient, except for specific methods papers. 
For transferability of the test method it is 
beneficial to have SOPs or other documents 
covering each component of the test method 
and the whole testing process
 
Non-disclosure of SOP is acceptable if full 
performance/readiness criteria are given. 
 
E.g., for media, plates, coating it should be 
defined what is acceptable/non-acceptable 
and how this is controlled. Test chemical 
identity and purity (certificate of analysis) and 
safety data sheets for chemicals
 
Mainly referring to specific/functional  
endpoints
Helps to interpret the results.  
Helps to interpret the results. 
 
Positive controls for analytical method may 
differ from controls for test/endpoint
E.g., neurite outgrowth, cytotoxicity 
Here: if cytotoxicity is not main endpoint
Control of cytotoxicity in a different format 
(e.g., other types of plates; other time point, 
is very problematic). Measuring cytotoxicity 
under the same test conditions as the main 
end point helps to interpret the mechanism 
related to the adverse effects for the main 
end point (specific or cytotoxicity-driven 
mechanism)
Usually at least three types of assay required 
(measurement of viability, measurement of cell 
death, single cell analysis) 
E.g., neurite outgrowth, migration inhibition in 
non-cytotoxic concentration ranges 
Testing for cytotoxicity only at the end of the test 
may give false negative data if cells die early 
and this is no longer detectable at later time 
points because of compensatory proliferation.
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Criteria Description Examples / Why is it important Max. score
5e  
Timing after test 
 
5f  
Curve fitting
5g  
Non-cytotoxicity 
 
 
5h  
Bench mark response 
5i  
Apoptosis/ 
proliferation
6 Test method 
controls
6a  
Positive controls (PC) 
 
 
6b  
Negative controls 
(NC) 
 
 
6c  
Unspecific controls 
(UC)
6d  
Endpoint-specific 
controls (EC) 
 
 
 
 
 
 
7 Data evaluation
7a  
Outliers
7b  
Concentration 
-dependence 
 
 
7c  
Benchmark response 
 
0.5 
 
 
0.5 
0.5 
 
 
 
0.5 
 
0.5 
 
4 
1 
 
 
 
1 
 
 
 
 
1 
 
1 
 
 
 
 
 
 
 
 
4
1 
1 
 
 
 
 
1 
 
For very short endpoints, e.g., 
electrophysiology measured 30 min after 
toxicant exposure, delayed measure of 
cytotoxicity is necessary
Sufficient non-toxic data points (baseline);  
at least 40% toxicity / change to allow fitting
Absence of ‘cytotoxicity’ does not mean non-
cytotoxicity (question of power): Has data 
variation been considered; is a measure of 
uncertainty given for non-cytotoxicity (e.g., 
BMCL calculation)?
Has a rationale been given for setting a 
threshold value for cytotoxicity (statistical or 
biological significance)
If natural feature of the test system: measure 
for normal rate required 
 
≥ 3 toxicants required for test definition; 
preferentially with different mechanisms; 
preferentially human-relevant toxicants; 
indicate variation of PC within and across 
assays.
≥ 5 negative controls are required to define 
specificity at ±20% level; concentration 
of negatives needs to be defined and 
rationalized 
 
A type of negative control for functional 
assays: not inactive, but only cytotoxic  
To provide plausibility and to help initial test 
setup: EC show that pathways considered 
to be relevant for test endpoint indeed affect 
the test endpoint. EC help to correlate (by 
concentration and time) compound effect on 
pathway (activity measure to be established) 
and on test endpoint (standard test 
readout). EC may be chemicals or siRNA; 
pathways may be defined from literature or 
experimentally (gene expression)
Procedure for handling and documentation 
should be established
Higher confidence in concentration-
dependent data; no-effect concentrations 
must be included (full range curve); data 
need sufficiently dense spacing around 
benchmark concentration; preferably provide 
statistical significance for key data points
Give rationale for definition (statistical (after 
FDR correction) or biological). Provide power 
estimate if conclusions are drawn from 
negatives.
Cells cannot die in a very short time even if 
compound triggers lethal changes. Data for  
24 h exposure should be given. 
 
 
 
 
 
E.g., statistical: 3x standard deviation; 
biological: 90% viability; see also:  
http://invitrotox.uni-konstanz.de/ 
 
 
 
Used to define acceptability criteria, S/N ratio 
or z’-value of screen 
 
 
Ways to define negatives: (i) e.g., compound 
only acting when metabolized, (ii) acting 
on another organ, (iii) known to be safe for 
pregnant women, (iv) is selective for another 
assay, (v) pairs/matches of a specific positive 
control (e.g., inactive metabolite)
Absolutely essential to define baseline 
variation and thus the relevant benchmark 
response for positive hits
E.g., actin is required for migration, thus an 
actin inhibitor should affect migration endpoint 
 
 
 
 
 
 
 
Here: referring to main endpoint(s)
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Criteria Description Examples / Why is it important Max. score
7d  
Curve fitting 
 
8 Testing strategy
8a  
Hazard prediction
8b  
Link to an AOP
8c  
Role in battery  
8d  
Comparison to similar 
tests
9 Robustness
9a  
Reproducibility 
9b  
Intra-lab
9c  
Inter-lab
9d  
Historical controls
10 Test benchmarks
10a  
Sensitivity (of the test) 
 
 
10b  
Specificity (of the test)
10c  
Acceptance criteria 
10d  
Response 
characteristics
11 Prediction model
11a 
Definition 
 
 
 
 
 
 
 
11b  
Rationale 
1 
 
 
4
1 
1 
1 
 
1 
 
4
1 
 
1 
1 
1 
4
1 
 
 
 
1 
1 
 
1 
 
4
1 
 
 
 
 
 
 
 
 
1 
 
Indicate detailed procedure used for curve 
fitting; preferentially force fitted curve 
through 100% at negative control conditions 
(full function)
Which hazard is assessed? Which question 
does the test method answer?
Does the test give input to a mechanistic 
concept, e.g., an AOP?
Full score for stand-alone tests. For tests 
that are not stand-alone, information on their 
relation to other tests in a battery is required.
Does the test fill a gap in a battery? Is it 
providing advantages compared to another 
test for the same hazard?
Data available on normal variation; 
information on factors affecting test variation 
is given
Data available from different operators and 
different test runs over longer time
Data available on transferability / 
reproducibility in another lab
Data for PC and NC over time 
Signal noise ratio (S/N) defined; Sensitivity 
information available 
 
 
Tested with sufficient number and quality of 
negative controls
Clearly defined and documented; Normal 
range of variation known 
Should the response be linear? What are the 
upper and lower limits?
 
Information should be available and 
clear (including rationale for model, i.e., 
its particular strengths). Information and 
rationale should be given for use of sharp 
thresholds or probabilistic approach. 
 
 
 
 
Reason, and mathematical basis / 
plausibility for prediction model given 
E.g., sigmoidal, linear or exponential curve fit
 
 
 
 
Helps to position test in battery; helps to 
interpret results
Information is required on how the test data 
would be used in a battery and under which 
conditions this is possible. 
Avoid overlapping tests being performed; 
ensure adequate testing battery/strategy
 
Historic control data on positive controls 
show normal range; known artefacts and 
shortcomings
 
 
 
S/N based on adequate data sets. The S/N 
is used to determine the limit of detection. 
Additional measures: True positive rate, hit 
rate, sensitivity to detect a panel of positive 
controls, etc.
Additional measures: true negative rate, etc. 
E.g., a given positive control has to reduce the 
main endpoint by at least 25%, otherwise test 
plate is discarded.
Additional measures: mono-directional or 
bi-directional deviation defined, information on 
accuracy, precision, limit of quantification, etc.
Information on how many classes of toxicants 
are predicted. Positives and non-positives; or 
strong, medium, weak positives. Information 
on uncertainty of prediction should be given, 
at least for positives (note that uncertainty of 
negatives is often not defined). 
E.g., you can define a sharp threshold (all 
above 4 is positive) or you can define a 
probabilistic approach (above 4 has a 70% 
likelihood to be positive)
Reason for the choice and value of thresholds  
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by a process that assembles all relevant information in a “read-
iness dossier”, including data not easily found in publications, 
e.g., provided by test developers and applicants. 
This clustering of scoring criteria is an important concept, 
as it provides individual scores for phases of test development. 
Phase I concerns all criteria that can be fulfilled during initial test 
method development. Phase II criteria refer to the test method 
performance based on, e.g., evaluation of replicates to conclude 
on robustness and reproducibility. Phase III is optional as a prop-
er screening is not always feasible for each test method, i.e., 2nd 
and 3rd tier methods. This allows a distinction of readiness for, 
e.g., academic research purposes, screening and prioritization, 
or regulatory risk assessment. The example of the UKN2 test 
shows that a method can have a high readiness level for screen-
ing, but still needs further improvement of hazard assessment of 
individual compounds in the context of a risk assessment process 
(Fig. 3).
3.3  Exemplary DNT test methods and their 
preliminary evaluation for readiness
To demonstrate the application of readiness scoring for DNT as-
says, a set of 17 test methods was selected, and the scoring was 
performed. Notably, the information used had to be extracted 
3.2  Scoring system for readiness criteria
According to the OECD GD 211 (OECD, 2014b), the new 
generation of in vitro test methods may be very useful for some 
regulatory purposes, even if they are not yet officially validated. 
For instance, they may be used to provide additional/supplemen-
tary mechanistic information on top of standard testing results. 
Moreover, such tests may be used in companies or regulatory 
authorities for internal decision making, or for screening pro-
grams with the aim of prioritizing substances for further testing 
(Browne et al., 2017). Although there is guidance on what needs 
to be considered for test method validation, not many tools are 
available that provide an actual measure of readiness.
Since readiness needs to be quantified to a certain extent, a 
simple scoring system was established with the intention of pro-
viding a rough quantification of readiness levels. In the future, 
such a system may be further refined, concerning the criteria 
considered, the weight given to the criteria, and especially by 
providing guidance on how the scoring is performed. Here, the 
system was kept simple, by assigning a maximum score to each 
criterion (see fourth column in Tab. 2), and by establishing a 
simple tool for clustering of scores (Fig. 3). The scores were 
assigned on the basis of publicly available information extracted 
from publications. The process may be facilitated in the future 
Criteria Description Examples / Why is it important Max. score
11c  
Confirmation
11d  
Limitations 
12 Applicability 
domains
12a  
Chemicals 
12b  
Pathways
12c  
AOP
13 Screening hits
13a  
Hit definition 
13b  
Hit confirmation 
(prim.) 
 
13c  
Hit confirmation (sec.) 
13d  
Screen documentation
1 
1 
 
3 
1 
 
1 
1 
4
1 
 
1 
 
 
 
1 
 
1
Experimental testing of prediction model; 
confirmation of function/predictivity
Information on limitations of prediction model 
and on how exceptions and special cases 
are to be handled 
 
Is information on the types of chemicals that 
fall into the prediction model / testing range 
available?
Type of pathways that are relevant for the 
test (to be disturbed or to be detected)
Information contributed to an AOP KE/MIE; 
element of a KE testing battery
Transparent, pre-defined criteria (including 
curve-fitting/statistical procedure) 
Independent test run(s) in “same” test 
method; full concentration-response 
 
 
Additional test (different from primary test 
method) confirming hit on same endpoint as 
screen
Acceptability criteria, performance of positive 
controls, internal robustness controls
 
Strange curve shapes, solubility issues, assay 
interferences, etc. 
How special chemical classes are handled
 
 
 
 
 
Usually, non-hits are discarded. If statements 
on non-hits are made, they need definition and 
power calculation.
Often loose (soft) criteria for hits, and 
no correction for false discovery rate. 
Confirmation assays can counteract such 
problems; use of new cells and new compound 
stocks provides additional robustness.
E.g., migration may be measured by tracking 
cells (primary test) and then (secondary test) 
by a Boyden chamber method.
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Differentiation of pluripotent stem cells into neural precursor  
cells (UKN1 test)
This test is exemplary for tests examining processes in the em-
bryonic (very early) phase of brain development. A very early 
step in embryonic development is the lineage specification of the 
cells of the inner cell mass into the three germ layers, endoderm, 
mesoderm and ectoderm (Leist et al., 2008b). The ectoderm is 
further divided into neural ectoderm, which gives rise to the cen-
tral nervous system, and the non-neural ectoderm. 
The UKN1 test method mimics this early neuroectoderm lin-
eage specification. Human pluripotent or embryonic stem cells 
(hPSC or hESC) are differentiated into early neuroectoderm pro-
genitor cells. This stage is reached after 6 days under the given 
assay conditions (prevention of SMAD signaling) (Balmer et al., 
2012; Balmer and Leist, 2014). The differentiation is extensively 
from the published literature, and thus some information may 
have been missed or may not have been taken into account. It 
is also important to note that some methods were not devel-
oped specifically for regulatory use. In such cases, information 
retrieval was from multiple publications, and there were un-
certainties and ambiguities concerning several criteria. A more 
formalized process of information retrieval might lead to higher 
scores. The selection of scored test methods was meant to give a 
representative overview of what is available to test interference 
of chemicals with various neurodevelopmental processes. The 
selection does not purport to be complete. 
The individual scoring information can be found in Table S13. 
A summary overview is given in Table 3. In the following, some 
additional details are given on the test methods that have been 
considered here.
Fig. 3: Scoring system for readiness criteria
Overview of the scoring system for the readiness criteria. The 13 criteria are sorted into three phases. Each area has various sub-items  
and the number of points that can be obtained is indicated in Table 2. Phase I includes the basic features of the test method as they would 
be provided by academic researchers. They include biological plausibility of the test method, features of the test system, and the availability 
of controls. A high number of points can be obtained for test system description (10 out of 35), as this is very important at early stages of 
test development. However, still two thirds of the points come from other areas not to be neglected. Phase II relates to the implementation 
of a test for practical applications in industry or for regulatory purposes. Here, the relation to a testing strategy, good robustness, and the 
availability of a prediction model are important. Phase III is optional as not each test method is used for a screening approach. Notably, not 
all points apply to all tests. In the preliminary rating scheme suggested here, these items are then scored positive automatically (labeled 
in italics in Tab. 2). Each phase is evaluated independently, and then categorized into one of four readiness classes (A-D). In the figure, an 
example is given for the rating of the cMINC (UKN2) test method. It would score as “A” (largely ready) in phase I, and as “B” in phase II.  
For phase III, it would score as “A”.
3 doi:10.14573/altex.1712081s
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characterized by whole transcriptome analysis, showing that the 
differentiation protocol results in a homogenous neuroepithelial 
progenitor (NEP) cell population with an anterior gene expres-
sion patterning. The process has been extremely well character-
ized on the level of transcriptome and epigenetic changes (Shin-
de et al., 2015, 2016; Rempel et al., 2015; Balmer and Leist, 
2014; Weng et al., 2012, 2014). A change in this gene expression 
pattern indicates a wrong differentiation track and may help to 
measure KEs such as neural tube patterning or neural differenti-
ation (Rempel et al., 2015; Tonk et al., 2015; Krug et al., 2013). 
The evaluation of UKN1 with our suggested criteria list re-
vealed that the system is ready concerning phase I. For phase II, 
the transferability to another laboratory is missing, as well as a 
final confirmed prediction model. It is a challenge to set up a pre-
diction model based on gene expression data alone. Therefore, 
anchoring of data to a functional endpoint (rosette formation) 
will be included (Waldmann et al., 2017). Regarding the screen-
ing issue of phase III, this test method reaches a readiness level 
of “B”, which means improvements are required. 
Primary hNPC proliferation assay (NPC1)
Various assays are available to study KEs belonging within the 
fetal phase of brain development. Exemplary are the NPC tests, 
the PeriTox, and the NeuriTox assay. NPC proliferation is a 
fundamental neurodevelopmental KE that, when disturbed, like 
in Zika virus-infected primary NPC, leads to microcephaly in 
children (Tang et al., 2016; Devakumar et al., 2018). 
Proliferation of primary hNPC of fetal origin (Lonza), grown as 
neurospheres in 3D, is studied by measuring the increase in sphere 
size over 14 days using phase contrast microscopy (Baumann et 
al., 2014, 2015; Gassmann et al., 2010, 2012; Moors et al., 2009; 
Schreiber et al., 2010; Tofighi et al., 2011) and/or by measuring 
bromodeoxyuridine (BrdU) incorporation after 3 days in vitro 
(DIV) using a luminescence-based BrdU assay (Roche) and a 
luminometer (Baumann et al., 2014, 2015). Briefly, neurospheres 
with a diameter of 300 µm are plated one sphere/well in a 96-well 
plate with or without chemical in epidermal growth factor (EGF)- 
and fibroblast growth factor (FGF)-containing defined medium. 
For neurosphere diameter assessment, phase-contrast microscopic 
images are taken on plating day (day 0) as well as on days 7 and 
14. Changes in sphere diameter are measured and monitored with 
ImageJ for each individual sphere. The same set-up is used for the 
BrdU assay, where BrdU incorporation into the DNA of hNPC is 
measured using a luminometer. The endpoint-specific control for 
this assay is withdrawal of growth factors, significantly reducing 
hNPC proliferation. This assay is part of a “high content DNT 
test”, the “Neurosphere Assay” (NPC1-6), and is also set up with 
hiPSC-derived neurospheres as well as with spheres generated 
from prepared rat, mice or rabbit brains (Baumann et al., 2016; 
Barenys et al., 2017, unpublished data) 
Scoring of the assay with our suggested list of criteria revealed 
that the system is ready (scoring A) concerning phase I. For 
phase II the assay also scored A, although the transferability to 
another laboratory is missing and the prediction model needs fi-
nalization. This is currently under development with a large data 
Tab. 3: Overview of the readiness levels of exemplary  
DNT test methods 
Different DNT test methods were scored according to the criteria 
presented in Table 1 and Figure 3. The readiness levels for  
Phase I-III varied from D (not at all ready), over C, B to A (largely 
ready), see Fig. 3. For detailed data see Table S11. The overall 
readiness was estimated semi-quantitatively from the pattern 
of readiness in the different phases. Notably, the term overall 
readiness has to be used with care, as readiness depends on 
the purpose, and it is given here only to provide an orientation on 
the availability of methods in the field. This is exemplified by the 
cMINC (UKN2 method) which scores A in Phase I and B in Phase 
II. According to this, the method is not ready for regulatory risk 
assessment. However, it scores A for screening, and is thus ready 
for initial prioritization of compounds. 
Abbreviations: UKN1, PSC differentiation into NPC/NSC embryonic 
phase differentiation; NPC1, hNPC proliferation; NPC2, hNPC 
migration; NPC3, hNPC neuronal differentiation; NPC4, hNPC 
differentiated neurons; NPC5, hNPC oligodendrocyte differentiation; 
NPC6, hNPC oligodendrocyte maturation and TH disruption;  
UKN2, NCC proliferation and migration; MESn, Morphological ESC 
to neurons; 3Dr, astrocytes, oligodendrocytes, myelination,  
microglia in 3D rat; 3Dh, astrocytes, oligodendrocytes, myelination, 
microglia in 3D human, foetal phase; UKN4 (NeuriTox), neurite 
outgrowth of central neurons; UKN5 (PeriTox), neurite outgrowth 
of peripheral neurons; NSR, neuronal subtype ratio, neuronal 
maturation; Syn, synaptogenesis; Nnff, neuronal network formation 
and function; ZFE, zebrafish
Readiness/ Phase I Phase II Phase III Overall  
Test method    readiness
UKN1 A B B B+
NPC1 A A A A
NPC2 A A A A
NPC3 A A B A-
NPC4 A B C B
NPC5 A A B A-
NPC6 A B B B+
UKN2 (cMINC) A B A A-
MESn C D D D+
UKN4 (NeuriTox) A A A A
UKN5 (PeriTox) A B A A-
NSR C D D D+
SYN B B B B
Nnff B A B B+
3Dr A A A A
3Dh B C C C+
ZFE B B A B+
1 doi:10.14573/altex.1712081s
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The NPC2 assay for total cell migration is also established for 
NPC prepared from rat, mouse or rabbit brains (Baumann et al., 
2016; Barenys, unpublished data).
Scoring of the assay with our suggested criteria list revealed 
that the NPC2 assay is ready (scoring A) concerning phase I. 
For phase II the assay also scored A, only the prediction model 
needs finalization. This is currently under development with a 
large data set. Concerning the screening issue of phase III, this 
test method also scores A.
Primary hNPC neuronal differentiation assay (NPC3)
Primary hNPC of fetal origin (Lonza) grow as neurospheres 
in 3D (see NPC1). Plating of size-defined (300 µm diameter) 
spheres on a poly D-Lysin/laminin matrix in a 96-well plate or 
8-chamber slide format in the absence of growth factors initiates 
radial NPC migration out of the plated sphere (NPC2) accompa-
nied by consecutive cell differentiation into nestin+ radial glia, 
β(III)tubulin+ neurons and O4+ oligodendrocytes (Moors et al., 
2012; Edoff et al., 2017; Baumann et al., 2014, 2015) over a peri-
od of one to five days (Schmuck et al., 2017). Neuronal cells are 
identified by positive β(III)tubulin staining within the migration 
area of each neurosphere three or five days after plating either 
manually or by using the Omnisphero platform (Schmuck et al., 
2017; 5). With this program, DAPI-stained nuclei are identified. 
An algorithm specifically created for small, young neurons with 
short neurites identifies β(III)tubulin+ neurites and secondarily 
finds the belonging nucleus by its association with the skeleton-
ized neurite. By comparing this Omnisphero algorithm to the 
Neuronal Profiler Bioapplication (NPBA), a program that is cus-
tomized for studying neuronal morphology with the Cellomics 
Array Scan (Thermo Scientific), we reduced the false-positive 
neuronal identification rate from 40% to < 10%. NPC3 can be 
multiplexed with NPC4 (neuronal morphology, see below) or 
NPC2 (radial glia and neuronal migration, see above); in the 
latter, information on neuronal (β(III)tubulin+ cell) positioning 
is further processed to values of neuronal migration (Schmuck 
et al., 2017). In addition, multiplexing of NPC3 with NPC2 and 
NPC5 (oligodendrocyte differentiation and positioning, see be-
low) after five days in vitro reveals information on neuronal and 
oligodendrocyte differentiation and migration within one assay 
(Schmuck, unpublished data). 
Scoring of the NPC3 assay with our suggested criteria list 
revealed that the assay is ready (scoring A) concerning phase I. 
For phase II the assay also scored A, only the prediction model 
needs finalization. This is currently under development with a 
large data set. Concerning the screening issue of phase III, this 
test method reaches level B of readiness.
Neuronal morphology (neurite number, average and total  
neurite length, neurite branching) of young  
neurons differentiated from fetal hNPC (NPC4)
The outgrowth of neurites is a major process during brain de-
velopment. It is needed for the formation of dendrites and axons 
and is therefore a pre-requisite for connectivity of neurons. A 
disturbed or impaired neurite outgrowth during human brain 
set. Concerning the screening issue of phase III, this test method 
also reaches A.
Primary hNPC migration assay (NPC2)
Cortex development takes place during the fetal phase of 
development. It involves radial glia migration leading to the 
development of a scaffold that is subsequently used by neurons 
as a set of “highways” to migrate and reach their final cortical 
destination. In contrast to rodents, human brain is gyrencephalic 
and radial glia composition of gyrencephalic species differs from 
that of non-folded brain surface species (Borrell et al., 2014). 
Thus, NPC migration is a fundamental neurodevelopmental KE 
that, when disturbed, e.g., in methylmercury exposed children, 
leads to alterations in cortex development (Choi et al., 1989). 
Primary hNPCs of fetal origin (Lonza) are grown as neu-
rospheres in 3D (see NPC1). Plating of size-defined (300 µm 
diameter) spheres on a poly D-Lysin/laminin matrix in a 96-well 
plate or 8-chamber slide format in the absence of growth factors 
initiates radial NPC migration out of the sphere. The first cells 
migrating out of the neurosphere display radial glia morphology 
and are nestin, SOX-2 and PAX-6 positive (Moors et al., 2007, 
2009, 2012; Edoff et al., 2017). Their migration is dependent on 
laminin-integrin interaction (Barenys et al., 2017), which is also 
known to be crucial for radial glia migration in vivo (Belvin-
drah et al., 2007). Moreover, treatment with bone morphogenic 
proteins (BMPs) causes glial fibrillary acidic protein (GFAP) 
enrichment accompanied by morphological changes towards 
star-like astrocyte cell shapes (Baumann et al., 2015). These data 
support the concept that these cells are radial glia cells (Moors 
et al., 2007, 2009; Baumann et al., 2016; Edoff et al., 2017). 
Secondarily, neurons and oligodendrocytes arise, the former 
migrating on the glia carpet (Schmuck et al., 2017). Hence, this 
multicellular secondary 3D model (Alépée et al., 2014) can be 
used for measuring a) radial glia cell, b) early neuronal, and c) 
oligodendrocyte migration. Radial glia cell migration is mea-
sured after 24 and/or 72 h by determination of the distance the 
cells cover from the sphere core to the furthest migrated cell 
using phase contrast microscopy (Baumann et al., 2015, 2016; 
Gassmann et al., 2010, 2012; Moors et al., 2007, 2009; Schmuck 
et al., 2017; Barenys et al., 2017; Tofighi et al., 2011; Edoff et 
al., 2017) or applying high content image analysis (HCIA) and 
the Omnisphero program4 to DAPI-stained spheres (Baumann 
et al., 2016; Schmuck et al., 2017). When the latter approach 
is multiplexed with β(III)tubulin-stained neurons or O4-stained 
oligodendrocytes, the Omnisphero program quantifies not only 
radial glia cells, but also neuronal and oligodendrocyte migra-
tion simultaneously (Schmuck et al., 2017). Migration cues 
differ between radial glia cells and neurons, as EGF stimulates 
radial glia and does not affect neuronal migration at very low 
concentrations, while at higher exposure levels both cell types 
are responsive to the EGF cue. EGF also stimulates migration 
in vivo (Puehringer et al., 2013). This assay assesses early fetal 
neuronal and oligodendrocyte differentiation at the same time, 
yet these are described as separate assays (NPC3 and NPC5, see 
below), as they can also be studied without migration measures. 
4 http://www.omnisphero.com
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disruptors when % oligodendrocyte decreases accompanied by 
no change or reduction in QM TH + compound in a concentration-de-
pendent manner, respectively. This assay can also be performed 
in mouse and rat NPC, but the mode of action of TH and its dis-
ruptors is different in rodent compared to human NPC (Dach et 
al., 2017).
Scoring of the assay NPC6 with our suggested criteria list re-
vealed that the assay is ready (scoring A) concerning phase I. For 
phase II the assay scored B, and in phase III this test method also 
reaches level B of readiness.
The cMINC neural crest cell migration assay (UKN2 test)
Neural crest cells differentiate during neurulation from the cells 
of the neural roof plate. These cells eventually give rise to over 
100 different cell types in the human body, including the pe-
ripheral nervous system, melanocytes, cardiomyocytes or facial 
connective tissue (Huang and Saint-Jeannet, 2004). One major 
feature of neural crest cells is that they migrate to the different 
parts of the developing embryo and differentiate to the accord-
ing cell type once they arrive at their final destination. A large 
percentage of developmental disorders (e.g., congenital heart de-
fects, orofacial clefts, Hirschsprung’s disease) is caused by NC 
cell (NCC) deficits. These kinds of alterations can be induced by 
genetic factors (Lee et al., 2009) or exposure to pharmaceuticals 
(e.g., valproic acid, Fuller et al., 2002) and pesticides (e.g., triad-
imefon, Menegola et al., 2005).
For the migration inhibition of neural crest cells (cMINC as-
say), human pluripotent stem cells are differentiated into HNK-
1+/DLL- neural crest cells. The cells are then further expanded 
for up to 30 days before freezing. The differentiated cells are 
thawed and seeded in 96-well plates supplemented with a silicon 
stopper that creates a 2 mm cell-free area. Migration is initiated 
by removal of the stopper, and the number of viable cells is mea-
sured after 48 h (Nyffeler et al., 2017a).
The evaluation of the MINC assay revealed an A-score for 
readiness for phase I and III as an extensive screen, including 
screen confirmation, was performed using the NTP library of 
chemicals (Nyffeler et al., 2017b). For full readiness in phase 
II, the transferability into other laboratories has to be shown and 
further responsible pathways and AOPs are missing. 
An additional feature of the assay is that other endpoints such 
as proliferation have been established and may be easily incor-
porated into standard testing.
Neuronal differentiation of pluripotent stem cells  
(various publications, MESn)
The UKN1 test method models early stages of embryonic neuro-
development by the differentiation of early anterior determined 
NPC. However, increasing numbers of differentiation protocols 
are published that enable differentiation of hESC or iPSC into 
other neuronal cell types. Each of these cellular systems is ready 
in terms of academic research and could serve as a starting point 
to develop new toxicological test methods. 
In these test systems, human ESC are differentiated directly 
to neurons. It is important that this stage of brain development 
is covered by a DNT test battery as several compounds such as 
ethanol, methylmercury and lead have shown to induce pertur-
development is thought to be one reason for the development 
of autism spectrum disorders. Therefore, this test method was 
developed in order to more rapidly assess chemical toxicity on 
the growth of neurites.
The NPC4 assay is an extension of the NPC3 assay when 
NPC3 is evaluated with the Omnisphero software (see above) 
because it quantifies morphological measures of stained, hu-
man fetal NPC differentiated, young β(III)tubulin+ neurons. 
Skeletonized neurites are evaluated for their number, length 
and branching (Schmuck et al., 2017). The test is a HCIA assay, 
which has been extensively characterized with two individual 
software programs versus manual evaluation of all endpoints, 
and thus there is high confidence in the outcome.
Scoring of the assay NPC4 with our suggested criteria list 
revealed that the assay is ready (scoring A) concerning phase I. 
For phase II the assay scored B, and in phase III this test method 
reaches level C of readiness.
Oligodendrocyte differentiation (NPC5)
Primary hNPCs of fetal origin (Lonza) grow as neurospheres 
in 3D (see NPC1). Plating of size-defined (300 µm diameter) 
spheres on a poly D-Lysin/laminin matrix in a 96-well plate or 
8-chamber slide format in the absence of growth factors initiates 
radial NPC migration out of the plated sphere (NPC2) accompa-
nied by consecutive cell differentiation into nestin+ radial glia, 
β(III)tubulin+ neurons and O4+ oligodendrocytes (Moors et al., 
2012; Edoff et al., 2017; Baumann et al., 2014, 2015) over a peri-
od of one to five days (Schmuck et al., 2017). Oligodendrocytes 
are identified by positive O4 staining within the migration area 
of each neurosphere five days after plating either manually or by 
using the Omnisphero platform (Schmuck et al., 2017; 5). Thus, 
DAPI-stained nuclei that co-localize for the epitope O4 are iden-
tified. The number of identified O4+ oligodendrocytes divided 
by the number of total nuclei in the migration area reveals % of 
differentiated oligodendrocytes (Baumann et al., 2016; Barenys 
et al., 2017; Dach et al., 2017; Schmuck et al., 2017). The end-
point-specific control BMP reduces oligodendrocyte differentia-
tion and accelerates astrocyte maturation in hNPC (Baumann et 
al., 2016) similar to its effects in vivo (Bond et al., 2012). NPC5 
can be multiplexed with NPC2 (migration), NPC3 (neuronal 
differentiation) and NPC4 (neurite morphology).
Scoring of NPC5 with our suggested criteria list revealed that 
the assay is ready (scoring A) for phase I. For phase II the assay 
scored A, and in phase III this test method reaches level B of 
readiness.
Oligodendrocyte maturation – Thyroid hormone (TH)  
disruption assay (NPC6)
Maturation of O4+ oligodendrocytes differentiated from 
hNPC is studied by quantifying myelin basic protein (MBP) 
mRNA expression divided by the % O4+ cells as assessed within 
NPC5. This ratio is defined as the oligodendrocyte maturation 
quotient (QM). During NPC development, QM strongly increas-
es upon treatment of cultures with triiodothyronine (T3; Dach 
et al., 2017). Human TH disruptors are identified by interfering 
with this process, i.e., when QM solvent control < QM TH + compound < 
QM TH. Oligodendrocyte toxicants can be distinguished from TH 
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addition, acrylamide is a known toxicant that induces neuropa-
thies in humans. 
In order to differentiate immature human dorsal root ganglia 
cells, human pluripotent stem cells are differentiated for 8 days 
resulting in neural crest cells. These progenitor cells can be 
frozen. After thawing the neural crest cells immediately start to 
grow neurites. One hour after thawing the cells are treated for 24 
h with test chemicals and stained with Hoechst and calcein. For 
imaging and quantification of viable cells and neurite area the 
principle is the same as in the UKN4 test method (see above) 
(Hoelting et al., 2016). 
The evaluation revealed that the PeriTox test has a full read-
iness score for phase I (scoring A), whereas for phase II the 
transferability to another laboratory has to be shown and a final 
prediction model needs to be developed and confirmed (scoring 
B). A first screening was performed with the 80 compounds of 
the NTP library (Delp et al., 2018). In phase III this test received 
scoring A.
Development of neuronal subtypes (e.g., different  
neurotransmitters, NSR) 
Perinatal exposure to low doses of toxicants such as lead and 
methylmercury can alter neuronal functions rather than leading 
to morphological alterations or to a net cell loss (Neal and Guil-
larte, 2010; Gimenez-Llort et al., 2001; Zimmer et al., 2011a,b). 
This effect may precede neurobehavioral and neurophysiological 
abnormalities that may also manifest long-term after exposure 
to the toxicant in later life (Tamm and Ceccatelli, 2017; Heyer 
and Meredith, 2017). Possible explanations concerning the mo-
lecular mechanisms are that such toxicants may interfere with 
expression of functionally relevant genes. Also, dysregulation 
of genes involved in the neurotransmitter metabolism can lead 
to, e.g., an altered ratio of neuronal subtypes. This might affect 
the patterning of the body axis or, later on, the homeostasis of 
the neurotransmitter system and eventually may affect neuronal 
function and connectivity, which could have implications in the 
adult organism. 
Approaches used to evaluate different neuronal subtypes are 
based on gene and protein expression of specific marker en-
zymes involved in the synthesis of specific neurotransmitters 
(i.e., glutamate decarboxylases (GAD1), tyrosine hydroxylas-
es, neurotransmitter transporters such as dopamine transporter 
(DAT), glutamate aspartate transporter (GLT) or the serotonin 
transporter (5-HTT)). Further, a toxicant may affect the ex-
pression of receptors of specific neurotransmitters. Profiling of 
relevant genes and/or proteins associated with neurotransmitter 
signaling have been performed on biased candidate genes by 
RT-qPCR (Zimmer et al., 2011a,b) and on whole transcriptome 
level during the maturation of neurons (Zimmer et al., 2011a,b). 
Together with functional endpoints, i.e., measurements of calci-
um flux, whole patch clamp or microelectrode arrays (see Neuro-
nal network formation and function below), this provides further 
indication of the ability of toxicants to disrupt neuronal activity 
due to previously altered gene expression.
Differentiating mESC have shown some potential to address 
this issue at a stage where most neuronal precursors are formed 
and maturation of neuronal subtypes takes place. The main end-
bations during this time window. The most common approach 
to assess morphological neuronal differentiation is by immu-
nohistochemistry for neuronal specific proteins such as neuro-
filaments, β(III)tubulin and Map2. Most studies combine the 
imaging approach with other quantitative measurements, e.g., 
Western blot (protein detection) or RT-PCR (mRNA expression). 
Several groups have developed protocols for the differentiation 
process; however, there is no harmonization between these dif-
ferent protocols. Furthermore, very few groups have tested more 
than one compound or generated concentration-dependent data 
and the main endpoints often show effects at cytotoxic concen-
trations. 
The performance criteria have been scored as the mean of five 
studies from different academic labs (He et al., 2012; Pal et al., 
2011; Senut et al., 2014; Stummann et al., 2009; Talens-Visconti 
et al., 2011). Publications that described a promising test system 
but did not test any compounds were not included. The score 
for phase I (C) indicates that the test method needs substantial 
improvements to be ready; the score of phase II (D) and III (D) 
shows that the test method is not ready at all for application. 
The main shortcoming of this test method is the few compounds 
tested, while the test system itself is promising and relevant for 
DNT. Once data is generated from reference compounds, this 
test method would likely be useful in a DNT testing battery. 
Similar tests have also been developed for murine ESC (Zim-
mer et al., 2011a,b; Kuegler et al., 2010) and may be used for 
species comparison. An interesting development is also the use 
of a 3D hiPSC-based system that has promising toxicological 
performance parameters (Schwartz et al., 2015)
The NeuriTox neurite outgrowth of CNS neurons test (UKN4)
For the establishment of this test method, immortalized prima-
ry cells derived from an 8-week old mesencephalon were used 
(Scholz et al., 2011). These cells are kept in a progenitor status 
by overexpression of v-myc under the control of a TET-off pro-
motor. Upon silencing of v-myc expression, the neuronal pro-
genitors differentiate into mature post-mitotic neurons in 6 days. 
In order to assess effects of chemicals on neurite outgrowth, the 
differentiating cells are plated after two days of differentiation 
into 96-well plates and are treated for 24 h (Krug et al., 2013). 
Then the cells are stained with Hoechst and calcein and imaged 
with an automated microscope. The viable cells and the neurite 
area are determined by double positivity and measurement of 
calcein-positive pixels. 
The evaluation of the UKN4 test method revealed a full readi-
ness for phase I criteria (scoring A); for phase II the transferabil-
ity of the method needs to be shown (scoring A). The cellular 
system including the differentiation has already been transferred 
into many different laboratories. A first screening was performed 
with the 80 compounds of the NTP library (Delp et al., 2018). In 
phase III this test also reached level A of readiness. 
The PeriTox neurite outgrowth of PNS neurons test (UKN5)
Besides the neurite outgrowth of CNS neurons, also the neurites 
of PNS neurons are sensitive targets of chemicals. A prominent 
example is the development of neuropathies during chemothera-
py with platinum compounds (Quasthoff and Hartung, 2002). In 
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genesis in vitro including (i) a commercially available kit based 
on HCIA (Thermo Fisher Scientific), referring to previously pub-
lished data (e.g., Harrill et al., 2015a,b); (ii) synapse microarrays 
(Shi et al., 2011) and (iii) protein (Viberg, 2009; Kim and Lee, 
2012) or mRNA analyses (Laurenza et al., 2013). These assays 
allow quantification of presynaptic (e.g., synaptophysin, syn-
apsin1, synaptobrevin, synaptogamin) and postsynaptic markers 
(PSD95, gephyrin, drebrin) at protein or mRNA levels as well as 
evaluation of their co-localization (HCIA).
The effects of chemicals on synapse function are routinely 
evaluated using whole-cell patch-clamp recording (Bal et al., 
2010) or microelectrode arrays (MEA) applied to neuronal 
networks (e.g., Hogberg et al., 2011; Vassallo et al., 2017) as 
described in this report (see Neuronal network formation and 
function below). 
However, to apply a synaptogenesis assay for routine chemi-
cal screening, it needs further development of the performance 
criteria, i.e., threshold for hits and data interpretation procedure.
The scores for phases I-III (all B) indicate that the test meth-
od is already well developed and standardized, however it still 
needs further optimization to fully satisfy the regulatory require-
ments. The test system itself is critical to complete a DNT in 
vitro testing battery. 
Neuronal network formation and function (Nnff)
These methods resemble early phases of brain development 
during which neuronal contacts are formed and become active. 
A few groups have used these methods to establish effects of 
developmental exposure to several compounds (including Me-
Hg, several insecticides and domoic acid) on the development 
of neuronal activity (Brown et al., 2016; Dingemans et al., 2016; 
Hogberg et al., 2011; Robinette et al., 2011). Primary cortical cul-
ture from rat neonates grown on microelectrode arrays (MEAs) 
that develop into spontaneously active neuronal networks over 
time (Cotterill et al., 2016; Brown et al., 2016; Dingemans et al., 
2016; Wagenaar et al., 2006) is the most established cell model 
for such measurements.
However, there is not yet much harmonization between these 
different protocols in terms of exposure window or exposure 
duration. However, for at least one of these protocols, the 
procedure has been published with a small set of positive con-
trols (Brown et al., 2016), and a set of 86 compounds has been 
screened that included 60 compounds known to cause DNT in 
mammals, of which nearly 82% altered at least one parameter of 
network formation (Frank et al., 2017). In addition to chronic/
developmental exposure, neuronal networks grown on MEAs 
are routinely used for acute exposure studies to determine effects 
on neuronal network function, which by now has been done for > 
1000 compounds (Strickland et al., 2017) using multiwell MEAs 
(mwMEAs). More recently, human iPSC-derived neuronal net-
works have been grown on MEAs (Tukker et al., 2016; Pamies 
et al., 2017a), although the degree of characterization of these 
human-based models and the number of compounds tested is 
currently limited. Regardless of the cell model used, MEAs can 
be multiplexed with cell viability assays such as LDH leakage, 
MTT and CellTiter Blue assays to distinguish neurotoxicity from 
cytotoxicity (Wallace et al., 2015). The scores for phase I (B), 
points addressed have been differentiation of neuronal subtypes 
and expression of specific neurotransmitter receptors and trans-
porters (Zimmer et al., 2011a,b; Sanchez-Martin et al., 2013). 
Importantly, adverse effects of tested toxicants (MeHg, Pb) on 
these endpoints were not related to growth inhibition or cytotox-
icity (Zimmer at al., 2011a,b; Sanchez-Martin et al., 2013). Al-
though these test systems are of murine origin, they are very use-
ful and helpful to investigate such toxic mechanisms, especially 
because human systems are rare. The test system as described 
in Zimmer et al. (2011a,b) (NSR: neuronal subtype ratio) and in 
Sanchez-Martin et al. (2013) was initially not developed as a test 
method and therefore would need further development to fulfill 
the readiness criteria as suggested here. The NSR test system 
reached scoring C for phase I and scoring D for phase II and III. 
The modern trend in toxicology is to use human cellular sys-
tems to investigate such toxic effects (Daneshian et at., 2016). So 
far, protocols to obtain glutamatergic, γ-aminobutyric acid (GA-
BA)ergic, dopaminergic or region-specific neuronal subtypes 
from hESC and hPSC have been published (Daadi et al., 2012; 
Gut et al., 2013; Begum et al., 2015), although no compounds 
have been tested for an effect on the differentiation process. 
A further trend in toxicology is to use 3-dimensional models 
(3D) to investigate the more complex cellular structure of the 
nervous system. These models are of high interest in neurotoxi-
cology and may be an opportunity to investigate possible shifts 
in neuronal subtypes. Moreover, they might be good test systems 
for investigations of cellular composition of neural cells, includ-
ing neurons and glial cells. Several human models have been 
developed recently using various techniques and based on differ-
ent cell sources such as cell lines (Smirnova et al., 2016; Simão 
et al., 2016), ESCs (Lancaster et al., 2013; Sandström von Tobel 
et al., 2014; Sandström et al., 2017a,b), and iPSCs (Pamies, 
2017a,b,c; Dang, 2016). These models have the capacity to dif-
ferentiate into various neuronal subtypes and different glial cells 
(see Glial cell differentiation and maturation below), making 
them suitable test systems for neurotoxicity and DNT. However, 
very few compounds have been tested in these systems, and pre-
viously developed assays generally need to be optimized to the 
3D condition. Therefore, there is currently no well-developed 
DNT test available using these human models. There will likely 
be a rapid increase in the use of these systems for DNT in the 
near future, especially as many groups have shown the relevance 
of using these systems to study neurological diseases and pathol-
ogies, e.g., Alzheimer (Choi et al., 2014, 2016), microcephaly 
(Lancaster et al., 2013) and Zika infections (Dang et al., 2016; 
Qian et al., 2016)
Neuronal maturation/neuronal network formation –  
Synaptogenesis (SYN)
The synapse formation assay allows to measurement of changes 
in the number of synapses induced by exposure to a compound 
that occurs during synaptogenesis. Impairment of synaptogen-
esis is an important KE in the existing AOPs relevant to DNT 
(Bal-Price and Meek, 2017; Bal-Price et al., 2017) since this 
key neurodevelopmental process is affected by different classes 
of chemicals (e.g., Shi et al., 2011; Viberg, 2009; Harrill et al., 
2011a,b, 2015a,b). Several approaches exist to measure synapto-
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2017; Shinozaki et al., 2017). Development-dependent changes 
in the expression of M1/2 phenotype markers of microglial cells 
have been observed upon toxicant exposure (Sandström et al., 
2017a).
Various test systems for glial differentiation (3Dr, 3Dh) have 
been evaluated for their readiness. The more complex 3D cul-
ture systems are required for measurements of myelination and 
neuro-inflammation, processes depending on complex cell-cell 
interactions. Using the suggested criteria list, the 3D culture 
systems derived from hESC or iPSC (Sandström et al., 2017b; 
Hogberg et al., 2013; Pamies et al., 2017a,c) were scored “B” for 
phase I and “C” for phase II and III. High readiness (A for phase 
I and II, B for phase III) was achieved by the 3D rat brain cell 
culture system (Monnet-Tschudi et al., 1993, 1996, 1999, 2000; 
Zurich et al., 2000, 2002, 2012).
Zebrafish assays
The zebrafish behavioral assays at early developmental stages 
(0-5 days post fertilization (dpf), considered non-animal testing 
according to EU legislation) have shown their potential as a 
whole organism approach to predict human DNT, complemen-
tary to in vitro assays (Nishimura et al., 2015; Padilla et al., 
2011; Garcia et al., 2016; Fritsche et al., 2015). These tests may 
be incorporated in a test battery in different ways (Fig. 4). The 
behavioral endpoints are readouts that integrate early events of 
central nervous system (CNS) development and functioning in a 
metabolically competent in vivo model system. Zebrafish brain 
development, anatomical features such as the blood-brain barri-
er, and physiology of early life stages are well described (Flem-
ing et al., 2013; Mueller and Wullimann, 2016; Schmidt et al., 
2013), while genetic and functional homology with humans has 
been demonstrated (Howe et al., 2013; Khan et al., 2017; Parker 
et al., 2013). Many brain subdivisions found in the developing 
mammalian brain are identifiable in the developing zebrafish, 
and neurotransmitters including GABA, glutamate, serotonin, 
dopamine, noradrenalin, and acetylcholine are found in the 
neurons of zebrafish at 1-5 dpf with spatio-temporal expression 
highly consistent with those in the mouse (Panula et al., 2010).
The zebrafish genome has been mapped and approximately 
70%-80% of zebrafish genes share homology with the human 
genome, and 82% of genes associated with disease in humans 
can be related to at least one zebrafish orthologue (Howe et al., 
2013). 
The stereotypic motor activity of the developing zebrafish in-
cludes three sequentially appearing behaviors that are in line with 
neurodevelopment: a transient period of alternating tail coiling, 
followed by responses to touch, and the appearance of organized 
free swimming of larvae (Nishimura et al., 2015). Behavioral 
assays for DNT in zebrafish include one or more of these three 
basic behaviors (Chen et al., 2012b; He et al., 2016; Selderslaghs 
et al., 2010, 2013; Jin et al., 2016) or some variants including a 
light stimulus in the photomotor response test (PMR) or light/
dark challenge (Ali et al., 2012; Jarema et al., 2015; Noyes et al., 
2015). These behaviors appear comparable at a functional level 
with human behavior, with links to neural circuitry underlying 
phase II (A) and phase III (B) indicate that improvements are 
still required to be ready, mainly regarding controls and harmo-
nization of exposure paradigms and methods of analysis. Once 
done, this test method would be a useful inclusion in a DNT 
testing battery.
Glial cell differentiation and maturation: assays to evaluate  
the potential role of astrocytes, oligodendrocytes,  
myelination, microglia, and neuroinflammation (3Dr, 3Dh)
Regarding glial cells, two types of disturbances may occur: 
(a) impaired development of the respective cell type; and (b) 
inflammatory over-activation of glial cells during the devel-
opmental period. The latter disturbance may have long-term 
consequences for brain structure and function: for instance, 
chronic neuroinflammation triggered during brain development 
was shown to be associated with Alzheimer’s pathology when 
aging (Krstic et al., 2012; Krstic and Knuesel, 2013), suggesting 
that the consequences of such DNT effects may only be revealed 
after a long asymptomatic delay (AOP-125). Assays to evaluate 
glial differentiation (astrocytes and oligodendrocytes) can be 
performed in 2D or 3D rodent models. Alternatively, cells may 
be differentiated from human ESC or iPSC, or from neural pro-
genitor cells (Alépée et al., 2014). 
Microglial cells in the brain are derived from yolk sack my-
eloid progenitors (Gomez Perdiguero et al., 2013). Microglial 
differentiation per se, in the brain, has not been studied as a DNT 
endpoint but, since microglia have an essential role in the neu-
roinflammatory process and in the removal of other dying cells 
(Hirt et al., 2000), their reactive potential may differ depending 
on their maturation state or tissue environment (Sandström et 
al., 2017a; Lund et al., 2006). Maturation of astrocytes can be 
assessed by a progressive decrease of vimentin expression and 
a progressively increased expression of GFAP and glutamine 
synthase (GS), as specific markers of astrocytes (Molofsky and 
Deneen, 2015). Toxicity to differentiating astrocytes would lead 
to a decrease of GFAP or GS levels, but it could also manifest by 
a re-expression of vimentin and mainly by an increased expres-
sion of GFAP over control level, as a sign of astrocyte reactivity 
(astrocyte activation is a typical sign of neuro-inflammation).
Oligodendrocyte differentiation and maturation can be evalu-
ated by measuring the sequential expression of markers of differ-
ent stages of differentiation (i.e., first SOX10, followed by NG2 
and O4, Gal-C, CNP, then MBP and finally MOG) (Rowitch, 
2004). In mixed cultures, oligodendrocyte maturation can also 
be quantified by studying MBP expression. Completion of the 
myelination process can be assessed by the presence of compact 
myelin sheets visualized by electron microscopy (Pamies et al., 
2017a).
Neuro-inflammation is mainly measured by glial reactivity, 
evidenced by increased expression of microglial and astrocyte 
specific markers (CD11b, Iba1, Isolectin B4, GFAP) and mor-
phological changes, accompanied by increased expression and 
release of pro-inflammatory cytokines (IL-1β, TNF-α, IL-6). Re-
active glial cells can acquire neurotoxic (M1, A1) or neuropro-
tective (M2, A2) phenotypes (Kigerl et al., 2009; Liddelow et al., 
5 https://aopwiki.org/aops/12
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48 h of compound treatment in a high content format (Breier et 
al., 2008; Radio et al., 2015).
4  Key neurodevelopmental processes covered 
by a battery of DNT in vitro assays 
Over the last decade, there has been a thorough effort to iden-
tify neurodevelopmental KEs that are essential for brain devel-
opment (Fig. 1) and can reliably be tested in an in vitro assay 
format. This task is complex as the developmental period of the 
brain is the longest compared to other organs – spanning from 
post-conceptual week four until the mid-20 years of age – and 
during the different phases of neurodevelopment various brain 
cell types perform distinct yet coordinated tasks. Neurodevel-
opmental processes in the context of timing and with a focus 
on human brain development are summarized in Silbereis et al. 
(2016), which serves as the basis for this chapter. The relevant 
processes are laid out here and corresponding in vitro assays 
that have the ability to detect changes in such are identified. The 
list of assays comprising a possible future testing battery can be 
found in Section 3.3 of this paper and is not repeated here. How-
ever, missing assays for certain neurodevelopmental processes 
are identified.
During early embryogenesis, embryonic stem cells commit to 
the neural lineage by becoming neural precursor cells (NPCs). 
These cells migrate and form the neural plate and subsequently 
the neural tube as the first defined structures of the brain. Later 
during development, the neural tube is called the subventricu-
lar zone, the area of cell origin (Kolb and Gibb, 2011). Assays 
capturing effects of chemical exposure on these endpoints 
include development of NPCs from hESC or hiPSC and stem 
cell-derived rosette formation. At this time, the rosettes resemble 
the neuronal tube structure in a two-dimensional (2D) format 
(Stummann et al., 2009; Colleoni et al., 2011, 2012; Senut et al., 
2014; Waldmann et al., 2017). Readouts are either morpholog-
the basic form of behavioral regulation. Consistent with mam-
mals, neural networks generate, e.g., periodic motor commands 
for rhythmic movements and visual challenges can result in anx-
iety-like behavioral effects (Nishimura et al., 2015). 
Many different zebrafish behavioral assays were reviewed by 
Legradi et al. (2015) and Planchart et al. (2016), concluding that 
there is a need for a harmonized protocol with recommendations 
for, e.g., inclusion of embryo teratogenic endpoints, positive and 
negative controls, and a standard exposure scenario. Neverthe-
less, the robustness of the behavioral endpoints has been demon-
strated through comparison among different assays of a small 
number of chemicals (i.e., three compounds: ethanol, valproate 
and pentylenetetrazole) in 7, 3 and 4 studies, respectively giving 
similar results (Legradi et al., 2015). 
The scoring for readiness considered aforementioned publi-
cations, covering screening of between 1 and 60 compounds, 
demonstrating compliance with a majority of performance cri-
teria with B for phase I and II, and A for phase III. Zebrafish be-
havioral analyses are promising tools, complementary to cellular 
assays, which will benefit from further protocol harmonization 
and defining screening hits. The behavioral assays might be 
strengthened through inclusion of mechanism-based assays (ax-
on growth, gene expression profiles, neurotransmitter activity) in 
relation to observed adverse outcomes (Chen et al., 2012a; He et 
al., 2016; Jin et al., 2016) and link to other human-based cellular 
model systems within the DNT battery.  
ReNcell CX-based proliferation assay
ReNcell CX cells (Millipore, Temecula, CA) are a myc-immor-
talized cell line derived from a 14-week gestation human fetal 
cortex growing as a monolayer. For the proliferation assay, cells 
are plated in laminin-coated 96-well plates. ReNcell CX cell 
proliferation is determined by quantifying DNA replication us-
ing the Cellomics BrdU Cell Proliferation Kit for high-content 
screening (Thermo- Fisher Scientific, Pittsburgh, PA) using the 
Cellomics ArrayScan. Proliferation is assessed after 4, 24, and 
Fig. 4: Incorporation of ZFE model in a 
low- and high-throughput mode battery 
of tests 
The zebrafish embryo (ZFE) test may be 
incorporated in various ways into a DNT 
test battery, depending on resources, lab 
automation and the purpose of testing. If 
ZFE testing allows only low-throughput, 
it may be used as second tier to further 
examine hits from other in vitro tests by a 
more complex whole-animal based test. 
Conversely, ZFE testing available as a 
high-throughput system may be used 
to identify primary hits that are further 
characterized and/or confirmed for human 
relevance by human cell-based in vitro 
tests. As a third approach, ZFE testing may 
be run in parallel with in vitro tests to feed 
data into an overall decision model.
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nal circuits mainly from hindbrain rhombomeres (Kiecker and 
Lumsden, 2005) and later neurogenesis during cortex formation 
from RG cell populations (Borrell and Götz, 2014). As for the 
early neurogenesis, methods for in vitro neuronal differentiation 
from hESC or lately hiPSC are established (Stummann et al., 
2009; He et al., 2012; Nash et al., 2012; Druwe et al., 2016; 
Pistollato et al., 2017; Zagoura et al., 2017). For later neurogene-
sis during corticogenesis, it seems advantageous to employ fetal 
cells that arise from the 2nd trimester of gestation (Hansson et al., 
2000) and which form neurons from RG neural precursors as in 
3D neurospheres from primary human fetal NPC, as described 
in the NPC3 assay (Moors et al., 2009; Baumann et al., 2015; 
Barenys et al., 2017) or equivalent stem cell-derived neurons 
with cortical features (Rigamonti et al., 2016). 
During brain development, more neurons are generated than 
needed, and final circuits are shaped by programmed death of 
surplus neurons that do not reach their target area. This has been 
modelled in primary neurons by conditions favoring hypo-polar-
ization (Gerhardt et al., 2001; Volbracht et al., 1999), and simi-
larly dedicated test methods may need to be devised for human 
neurons (Druwe et al., 2015).
In addition to neurogenesis, neuronal migration is a hallmark 
of cortex formation. Neuronal migration can also be measured 
by multiplexing the NPC2 and the NPC3 assays (Schmuck et 
al., 2017). After birth, newly formed and migrated neurons de-
velop further by massively growing out neurites, dendrites and 
axons, followed by synaptogenesis. These processes are indis-
pensable for neuronal network formation. Different neuronal in 
vitro systems allow measurements of these endpoints ranging 
from hESC- or hiPSC-derived neuronal monoculture (Harrill 
et al., 2011a; Druwe et al., 2016) or mixed cultures (Zagoura 
et al., 2017; Pistollato et al., 2017) to 3D hESC- or hiPSC-de-
rived mixed cultures (He et al., 2012; Rigamonti et al., 2016), 
LUHMES dopaminergic neuronal monocultures as in the UKN4 
assay (Scholz et al., 2011) or primary hNPC-derived mixed 
cultures using the NPC4 assay (Schmuck et al., 2017). Synapto-
genesis, however, has been quantitatively assessed in rat neurons 
via HCIA (Harrill et al., 2011b). As already mentioned in Section 
3.3, several different methods exist to measure synaptogenesis 
in vitro quantitatively, including a commercially available kit 
based on HCIA (Thermo Fisher Scientific). Recently, synapsin 
as a pre-synaptic vesicle protein was detected by staining in 
hiPSC-derived mixed cultures that contain GABAergic, glu-
tamatergic and dopaminergic neurons (Zagoura et al., 2017), 
however, neither synapse number nor protein expression were 
quantified. Functionality of synapses in these cultures was dis-
played by electrical activity on microelectrode arrays (MEA), 
i.e., spikes and bursts, but do not seem to present synchronized 
bursting as seen for rat primary cortical culture-derived net-
works (Brown et al., 2016, 2017) or hESC-derived cultures on 
MEA chips (Kapucu et al., 2012; Kiiski et al., 2013). Nonethe-
less, MEA measurements were already successfully applied for 
in vitro DNT testing during chronic exposure to domoic acid 
(Hogberg et al., 2011), including evaluation of different recep-
tor subtype involvement (Hogberg and Bal-Price, 2011), MeHg 
ical features of rosette formation or changes in gene expression 
levels below the cytotoxic threshold. On this basis, the transcrip-
tomics-based teratogenicity index was established (Waldmann et 
al., 2014; Shinde et al., 2016). 
During a phase of exponential growth, the neural tube expands 
to form the critical brain processes that establish the primary or-
ganization of the central nervous system. This involves prolifer-
ation of NPC, which can be measured with different cell systems 
in 2D, i.e., hESC (Talens-Visconti et al., 2011; Bai et al., 2013), 
hiPSC (Souza et al., 2016), myc-immortalized ReNcell CX (Brei-
er et al., 2008; Radio et al., 2015) or 3D, i.e., NPC (Gassmann 
et al., 2010; Schreiber et al., 2010; Baumann et al., 2015, 2016; 
Barenys et al., 2017). In the neurulating embryo during neural 
plate formation, neural crest cells (NCCs) emerge that will later 
develop into cell types of various tissues (e.g., bone, cartilage, 
neurons, and melanocytes). For terminal specification, NCCs 
migrate to their loci of function (Dupin and Sommer, 2012). Dis-
turbances in NCC migration might lead to, e.g., Wardenburg’s 
syndrome, Hirschsprung’s disease, craniofacial abnormalities 
like frontonasal dysplasia and others. Thus, the neural crest cell 
migration (MINC) assay is an important tool to study effects of 
chemicals on this endpoint (Dreser et al., 2015; Pallocca et al., 
2016; Zimmer et al., 2012, 2014; Hirsch et al., 2017).
For development of individual brain regions and connections 
between parts, distinct signaling is necessary, as illustrated by 
brain region-specific transcriptomic profiles in developing 
human brains (Miller et al., 2014). For human cortical devel-
opment, differences from other species like rodents include the 
appearance of a secondary proliferative zone that allows the 
massive expansion of the human cortex (Kriegstein et al., 2006; 
Hansen et al., 2010). Outer radial glia (oRG, or basic radial glia 
(bRG)) cells, which contribute the majority of human radial glia 
cells and reside in this outer subventricular zone, are thought 
to produce the greater part of human cortical neurons (Smart et 
al., 2002; Lewitus et al., 2013). Lack of oRG cells causes liss-
encephaly, a normal condition in, for example, mice, but a rare, 
severe brain malformation in humans. An assay which addresses 
RG cell migration is the human NPC2 assay (see Section 3.3; 
Moors et al., 2007, 2009; Barenys et al., 2017; Schmuck et al., 
2017). Initially migrating cells show RG cell morphology and 
express nestin and GFAP. Upon BMP treatment, they develop 
into star-shaped, GFAP expressing astrocytes. More detailed 
molecular knowledge on the specific type of RG cell differenti-
ated in these cultures will be helpful in the development of brain 
region-specific in vitro models.
The first neurons that already develop in human gestation 
week (GW) 4 are motoneurons (Bayer and Altman, 2007; O’Ra-
hilly and Muller, 2006). Several methods for the generation of 
motor neurons from ESC have been established and charac-
terized. With regard to neurogenesis in the context of cortical 
development, neocortical neurons start to arise from GW7 and, 
with some exceptions, the majority of neurons are formed pre-
natally, e.g., neocortical excitatory neuron generation ceases 
at GW27 (Workman et al., 2013;6). Here, one can distinguish 
between early neurogenesis creating the most essential neuro-
6 http://translatingtime.org
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dition, O4+ cells generated from human fetal NPC neurospheres 
can be used for oligodendrocyte formation in the NPC5 assay 
(Moors et al., 2009; Schreiber et al., 2010) and TH-dependent 
maturation evaluation in the NPC6 assay (Dach et al., 2017) 
as described in Section 3.3. The formation of mature myelin 
sheets is still challenging to obtain in vitro and the 3D structure 
is crucial for this process. The 3D rat brain cell system has one 
of the best-developed tests for this process (Monnet-Tschudi et 
al., 1999), however, the species difference is of concern. A few 
human models have recently been developed showing character-
istic myelin sheet morphology, but the test method needs to be 
further developed to fulfill the criteria of the DNT test battery 
(Sandström et al., 2017b; Pamies et al., 2017a).
5  The status of in vitro testing in the field of DNT
5.1  Which chemicals have already been tested in 
assays that can contribute to a DNT test battery?
An alternative approach towards evaluation of test readiness 
would be to examine which compounds known to be associated 
with a DNT hazard have been correctly or incorrectly identified 
by NAMs. This question can only be answered conclusively by 
data from an entire test battery, as no single in vitro method cov-
ers the whole spectrum of DNT-relevant processes. A small step 
towards this ultimate goal would be taking stock of the available 
data to see which chemicals have been tested, and which gaps in 
chemical and biological space would need to be filled. In a sub-
sequent step, generally applicable prediction models would need 
to be established in order to eventually compare the outcome of 
in vitro testing with knowledge on in vivo hazard.
We conducted a literature search investigating which of the 
32 compounds listed by Aschner et al. (2017) as DNT toxicants 
have been tested in vitro. The outcome of our survey shows (Tab. 
4) that only a few compounds (e.g., methylmercury) have been 
tested broadly, while for others (e.g., heroin) only limited in vitro 
data are available. However, testing this small subset of com-
pounds will not be sufficient. There are other positive controls, 
and, even more importantly, large numbers of negative controls 
need to be identified and tested to establish good prediction mod-
els. Thus, an important task for future research activities would 
be to close such data gaps by encouraging the development and 
use of a larger test set of chemicals to be used widely within the 
DNT in vitro field.
One step in this direction would be development of a database 
of all compounds tested to date in DNT alternative assays. So 
far, a summary list of chemicals already tested has been generat-
ed (Fig. 5). This figure illustrates the current status of chemical 
testing in assays that could be used as part of an IATA for DNT. 
The table was compiled based on publications describing various 
assays and requesting that the lead authors of those publications 
report which compounds they had tested. All chemicals were 
mapped based on conversion of CAS#s to DSSTOX ID num-
bers using the EPA Chemistry Dashboard7. Chemicals were not 
considered desalted, so there may be similar desalted chemicals 
(Dingemans et al., 2016) and several insecticides (Dingemans 
et al., 2016), and recently a set of 86 environmentally relevant 
chemicals (Frank et al., 2017). As briefly described in Section 
3.3, neuronal morphological and functional maturation (includ-
ing expression of functional receptors, ion channels, pathways 
involved in a range of cellular responses and defense mecha-
nisms, etc.) can be evaluated by immunocytochemistry specific 
protein staining, mRNA expression or pathway specific response 
measurements using specific agonists or antagonists. 
Human stem cell-based protocols need further optimization 
to improve neuronal and glial maturation in mixed cultures de-
rived from hiPSCs, which will be able to generate reliable and 
reproducible neuronal network activity. Such cultures should 
contain various cell types, as in vivo, of excitatory and inhibitory 
synapses originating from different neuronal subtypes grown 
in the presence of glial cells (astrocytes, oligodendrocytes and 
microglia). 
Indeed, besides neurons, glial cells are integral parts of the 
CNS, representing 50% of cells in the adult brain (Kuegler et 
al., 2012). Glia cell (astrocytes and oligodendrocytes) generation 
from RG by producing astrocyte and oligodendrocyte precursor 
cells generally follows neurogenesis and continues until after 
birth (Kleiderman et al., 2016a,b). 
Astroglia differentiation is a crucial event during brain devel-
opment because astrocytes create the brain environment, build 
up the micro-architecture of the brain parenchyma, maintain 
brain homeostasis, store and distribute energy substrates, control 
the development of neural cells, synaptogenesis and synaptic 
maintenance and provide defense strategies for the brain. There 
are different astrocyte types with different functions in the brain 
(Hu et al., 2016). Some in vitro systems recapitulate astrocyte 
development from hESC, hiPSC or hNPC (Talens-Visconti et al., 
2011; Zagoura et al., 2017; Moors et al., 2009). There is, howev-
er, a lack of precise astrocyte molecular characterization besides 
the expression of GFAP or vimentin that allows understanding of 
the astrocyte subtypes’ roles in such systems. Compound effects 
on astrocyte reactivity (Zagoura et al., 2017; Sandström et al., 
2017b), development (Moors et al., 2010; Baumann et al., 2015) 
or susceptibility (Talens-Visconti et al., 2011) are just beginning 
to contribute to the understanding of different astrocyte subtypes 
and functions in human cultures in vitro. Much more information 
is available on murine primary astrocytes (Falsig et al., 2006), 
or the combination of murine astrocytes with human neurons 
(Efremova et al., 2015, 2017), and fully humanized systems can 
be optimized to yield similar data.
Compared to other glial subtypes, oligodendrocyte myelin 
production is protracted in humans (Bradl and Lassmann, 2010). 
Given the inhibitory action of myelin on synapse formation 
and neuronal network plasticity, delayed myelination prolongs 
the development of learning activities, memory, and complex 
sensory perception. This species difference in timing highlights 
the importance of using human cells for complex in vitro oli-
godendrocyte or myelination models. Some of the recently 
developed methods for multiple sclerosis research referring to 
oligodendrocytes are summarized in Madill et al. (2016). In ad-
7 https://comptox.epa.gov/dashboard
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Fig. 5: The current chemical landscape of in vitro DNT testing 
The heatmap plots chemicals as rows and test status as columns. The first 5 columns provide evidence of the class of chemicals relative 
to evidence of DNT or priority for testing (see main text Section 5.1). The other columns list assays grouped by neurodevelopmental 
processes. A brief description of each column is provided below, along with a reference or references, if available. Compounds from 
columns A-E that have been tested in different assays (columns 1-31), are indicated by a blue (human), red (rodent), or green (alternative 
species) horizontal line. It should be noted that the information on which compounds have been tested was provided by the laboratories 
engaged in testing, and that not all of the data for each compound/assay pair have been published. Chemical class columns:  
A, Compounds with evidence of DNT from multiple laboratories (Mundy et al., 2015); B, Compounds with evidence of DNT from only one 
laboratory (Mundy et al., 2015); C, Compounds in the 87 chemical library supplied by the National Toxicology Program; D, Compounds 
subjected to the literature search in Mundy et al. (2015) that did not have evidence of DNT; E, Other compounds; primarily ToxCast 
compounds, but also assay positive controls and other miscellaneous compounds. 
Assay columns: 1, Proliferation in human neurospheres (Baumann et al., 2016); 2, Proliferation in hNP1 neuroprogenitor cells (Mundy  
et al., 2010); 3, Proliferation in ReNcellCX human neuroprogenitors (Breier et al., 2008; Radio et al., 2015); 4, Proliferation in mouse 
neurospheres (Fritsche et al., unpublished data); 5, Proliferation in rat neurospheres (Baumann et al., 2016); 6, Neuronal differentiation in 
human neurospheres (Baumann et al., 2016); 7, Oligodendrocyte differentiation in human neurospheres (Fritsche et al., unpublished  
data); 8, Differentiation in mouse neurospheres (Fritsche et al., unpublished data); 9, Neuronal differentiation in mouse neurospheres 
(Fritsche et al., unpublished data); 10, Oligodendrocyte differentiation in mouse neurospheres (Fritsche et al., unpublished data);  
11, Neuronal differentiation in rat neurospheres (Baumann et al., 2016); 12, Oligodendrocyte differentiation in rat neurospheres (Fritsche  
et al., unpublished data); 13, Apoptosis in human NP1 neural precursors (Druwe et al., 2015); 14, Migration of human neuroprogenitor  
cells; 15, Migration in human neurospheres (Baumann et al., 2016); 16, Migration in human neural crest cells (Nyffeler et al., 2017a,b);  
17, Migration in mouse neurospheres (Fritsche et al., unpublished data); 18, Migration in rat neurospheres (Baumann et al., 2016);  
19, Neurite outgrowth in human hN2 neurons. (Harrill et al., 2010); 20, Neurite outgrowth in human peripheral neuroprecursors (Hoelting  
et al., 2016); 21, Neurite outgrowth in LUHMES neurons (Krug et al., 2013); 22, Neurite outgrowth in human iPS-derived neurons (Ryan  
et al., 2016); 23, Neurite outgrowth in PC12 cells (Radio et al., 2015); 24, Neurite outgrowth in rat cortical neurons (Harrill et al., 2011a);  
25, Maturation of neurites in rat cortical neurons (Harrill et al., 2011b); 26, Synaptogenesis in primary cortical neurons (Harrill et al., 2011b); 
27, Neuronal network function – Acute (Strickland et al., 2017, in press); 28, Neuronal network formation – Developmental (Brown et al., 
2016); 29, Feeding, larval development and reproduction in C. elegans (Behl et al., 2016.); 30, Zebrafish behavioral tests (Cowden et al., 
2012; Padilla et al., 2011); 31 Zebrafish behavior 24 hr post-fertilization (Reif et al., 2016). 
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Cellular system NEP Neuro- ReNcell Neural hESC /  CNS 3D 3D 2D PNS Zebra 
 diff. spheres  crest hiPS neurons human rat cell  murine neurons fish 
    migration based  cell  culture  cell   
     diff.  culture  culture
Name of assay NEP NPC 1-6 ReNcell UKN2 UKN1 UKN4 3Dh 3Dr 2Dm UKN5 ZFE 
 diff.   (cMINC)  (Neuri    (PeriTox) 
      Tox)   
COMPOUNDS                      
Arsenic       1-3         4,5    
Cadmium     6,7 2 8     9 10   11
Chlorpromazine       1             12
Chlorpyrifos   13 7   14 15   16 17-20   
Cocaine         21       22   23
Dexamethasone     6   24-26      27   28
Diphenyldantoin                      
Domoic acid                 29,30   31
Ethanol         32-34       35   36
Haloperidol           15     37    
Heroin                      
Hexachlorophene                      
Ketamine         38       39,40    
Lead     6 41 24,42     43,44 10,19   45,46
Lindane                      
MAM   13            47    
Maneb                      
Tab. 4: Overview of testing status of DNT reference compounds, with respect to NAMs 
A subset of chemicals with strong evidence for a DNT hazard in vivo (as described in Aschner et al., 2017) was selected. A literature 
search was performed to retrieve data on in vitro testing of these compounds. Data for 11 assays have been compiled here. Pale blue 
fields indicate that no clear test data have been retrieved. Green fields indicate that the compound has been examined in the respective 
test method and was found to show a positive effect. Orange fields indicate that the compound has been tested but did not show any 
effect specific to DNT. In the latter two cases, the literature evidence is indicated. 
Each assay allows testing of specific DNT endpoints as indicated below: NEP differentiation, neural tube formation; NPC 1-6, NPC 
proliferation, radial glia migration, neuron and glia differentiation, neurite outgrowth; ReNcell, NPC proliferation; UKN2 (cMINC), NCC 
migration; UKN1, hESC/hiPS, neuron, astrocyte and oligodendrocyte differentiation, neurite outgrowth. UKN4 (NeuriTox), DA neuron 
differentiation, neurite outgrowth; 3Dh, human neuron, astrocyte and oligodendrocyte differentiation, synaptogenesis, myelination, 
neuronal network formation; 3Dr, rat neuron, astrocyte and oligodendrocyte differentiation, synaptogenesis, myelination, neuronal 
network formation, neuroinflammation; 2Dm, murine neuron and glia differentiation, synaptogenesis, neuronal network formation;  
UKN5 (PeriTox), neurogenesis; Zebrafish, brain development. 
Literature as indicated by numbers in the orange and green fields: 1. Zimmer et al., 2014; 2. Dreser et al., 2015; 3. Pallocca et al., 2016;  
4. Zhou et al., 2015; 5. Chattopadhyay et al., 2002; 6. Breier et al., 2008; 7. Culbreth et al., 2012; 8. Gulisano et al., 2009; 9. Monnet-
Tschudi et al., 1993; 10. Tasneem et al., 2016; 11. Chow et al., 2008; 12. Selderslaghs et al., 2013; 13. Baumann et al., 2016; 14. Lee et 
al., 2014; 15. Krug et al., 2013b; 16. Monnet-Tschudi et al., 2000; 17. Slotkin and Seidler, 2012; 18. Crumpton et al., 2000; 19. Visan et al., 
2012; 20. Dingemans et al., 2016; 21. Lee et al., 2017; 22. McCarthy et al., 2011; 23. Shang et al., 2007; 24. Harrill et al., 2011b; 25. Moors 
et al., 2012; 26. Ninomiya et al., 2014; 27. Bramanti et al., 2010; 28. Khor et al., 2013; 29. Perez-Gomez and Tasker, 2012; 30. Hogberg et 
al., 2011; 31. Tiedeken et al., 2005; 32. Palmer et al., 2012; 33. Talens-Visconti et al., 2011; 34. Nash et al., 2012; 35. Guadagnoli et al., 
2016; 36. Parker et al., 2014; 37. Benninghoff et al., 2013; 38. Bai et al., 2013; 39. Slikker et al., 2015; 40. Hondebrink et al., 2017;  
41. Zimmer et al., 2012; 42. Senut et al., 2014; 43. Zurich et al., 2002; 44. Monnet-Tschudi et al., 1999; 45. Dou et al., 2011; 46. Chen et al., 
2012a; 47. Hoareau et al., 2006; 48. Suarez-Isla et al., 1984; 49. Kindlundh-Hogberg et al., 2010; 50. Hondebrink et al., 2016; 51. Santos-
Fandila et al., 2015; 52. Stummann et al., 2009; 53. Schmuck et al., 2017; 54. Moors et al., 2009; 55. Wilson et al., 2014; 56. Pallocca 
et al., 2013; 57. Stiegler et al., 2011; 58. Sandström et al., 2017b; 59. Hoelting et al., 2013; 60. He et al., 2012; 61. Monnet-Tschudi et al., 
1996; 62. Popova et al, 2014; 63. Yao et al., 2017; 64. Coronas et al., 2000; 65. Sandström von Tobel et al., 2014; 66. Schreiber et al., 
2010; 67. Hirsch et al., 2017; 68. Xiong et al., 2012; 69. Tofighi et al., 2011; 70. Yang et al., 2014; 71. Markus et al., 2010; 72. Colleoni et al., 
2011; 73. Orsolits et al., 2013; 74. Addae et al., 2012; 75. Colleoni et al., 2012; 76. Wang et al., 2015; 77. Zimmermann et al., 2015.
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or unpublished at this time. Clearly, future work to populate a 
database with hit-call for these chemicals is needed.
Several important observations are immediately evident from 
Figure 5. First, for most assays, the total number of compounds 
tested is small and ranges from 25-100. A larger number of 
chemicals has been tested only in a smaller number of assays. 
Examples include ~2000 chemicals for acute network func-
tion (column 27) and zebrafish behavior (column 31); ~1000 
chemicals for neural cell proliferation (column 3) and neurite 
outgrowth (column 23). 
Importantly, there are many data gaps in the testing of com-
pounds for which there is information about their ability to cause 
DNT (compounds above the dashed line). Of the compounds with 
evidence for DNT, there are two subsets that have not been tested 
in any in vitro assay. The first consists of a variety of compounds 
which could be tested, but to date have not been, including some 
pesticides (e.g., fenvalerate, cyhalothrin, ivermectin), metals 
(e.g., arsenic, manganese dioxide) and pharmaceuticals (e.g., nal-
oxone, naltrexone, propranolol). The second untested set includes 
compounds that currently would be difficult to test in vitro, in-
cluding gases (carbon monoxide, carbon disulfide), volatiles (e.g., 
xylenes, trichloroethylene, tetrachloroethylene) or semi-volatiles 
(e.g., methanol, xylenes). This latter group highlights a need for 
mapped in more than one place (e.g., amphetamine sulfate will be 
in a separate row from amphetamine hydrochloride). The first set 
of columns A-E, provides an idea of the compound space that has 
been tested. Column A lists compounds identified as having in 
vivo studies from two or more laboratories indicating the ability 
to cause DNT in mammals, and column B for chemicals with on-
ly one laboratory (Mundy et al., 2015). Column C is a set of ~91 
high priority chemicals provided to investigators by the NIEHS 
National Toxicology Program. Column D is a list of chemicals 
from Mundy et al. (2015) for which no evidence was found for 
DNT. In most cases, the lack of evidence of DNT was likely due 
to a lack of any test data, so false negatives may be likely for 
the chemicals in column D. The remainder of the compounds in 
column E were primarily from ToxCast testing and/or assay-spe-
cific positive controls. The remaining columns group assays run 
by different laboratories in a manner consistent with KEs in the 
development of the nervous system; e.g., proliferation assays, 
differentiation assays, etc. If an investigator reported that a chem-
ical had been tested in a particular assay, then it is indicated by a 
colored horizontal bar in the appropriate column. Note that this 
is an indication that the compound has been tested in a partic-
ular assay, not a determination of whether that compound was 
positive or negative in the assay, and that data may be published 
Cellular system NEP Neuro- ReNcell Neural hESC /  CNS 3D 3D 2D PNS Zebra 
 diff. spheres  crest hiPS neurons human rat cell  murine neurons fish 
    migration based  cell  culture  cell   
     diff.  culture  culture
Name of assay NEP NPC 1-6 ReNcell UKN2 UKN1 UKN4 3Dh 3Dr 2Dm UKN5 ZFE 
 diff.   (cMINC)  (Neuri    (PeriTox) 
      Tox)   
COMPOUNDS                      
Manganese                 48    
MDMA                 49,50    
Methanol                     51
Methyl mercury 52 13,53,54 6 41 24,55,56 15,57 58-60 61 10,19,20,   12 
         62  
MPTP                     63
Nicotine                 50,64    
Paraquat           15 58 65      
PBDE   66   3,67         68    
PCB       2 69      70    
Perfluorate-PFOA                      
Perfluorate-PFOS                      
Terbutaline                 71    
Toluene                      
Trans retinoic acid 72   6,7   24       73,74    
Triethyl tin                      
Valproic acid 75 13   2,3,41        76   77
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impairment of certain signaling pathways. As described in 
Fritsche et al. (2017b), signaling pathways are known to be in-
volved in fundamental neurodevelopmental processes including 
NPC proliferation (e.g., BDNF-ERK-CREB, RTK-PI3K-AKT), 
NPC apoptosis (e.g., RXR activation, PGE2, RXR), radial glia 
proliferation (e.g., miRNA-17-92), neuronal and glial migra-
tion (e.g., mitogen-activated protein kinase (MAPK), PI3K, 
BDNF/TrkB, Reelin-Dab, PLCγ1), astrocyte differentiation 
(e.g., mTORC1-STAT3, Notch signaling), oligodendrocyte dif-
ferentiation and myelin formation (TH), neuronal differentiation 
(e.g., mTORC1, BDNF-ERK-CREB, TH, PKC), synaptogenesis 
(e.g., NMDA receptor activation, calcium signaling, BDNF-Trk, 
BDNF-ERK-CREB), and neuronal network formation (e.g., PIP 
metabolism, TH, BDNF-TrkB, BDNF-ERK-CREB). 
These pathways, if disturbed sufficiently, will lead to adverse 
neurodevelopmental outcomes and are therefore thought to serve 
as anchors for DNT in vitro assay development. In combination 
with basic information on chemical effects on signaling path-
ways (e.g., via ToxPi; Reif et al., 2010, 2013), DNT in vitro test-
ing results concerning key neurodevelopmental processes can 
be used to inform AOPs on the cellular level, and will thus be 
fundamental for the establishment of DNT AOP networks. Some 
of them, such as impaired neuronal differentiation, increased 
the optimization of the experimental set up of available in vitro 
DNT test systems for reliable exposure to volatile chemicals.
Also apparent from the Figure 5 heatmap is that among the 
different key neurodevelopmental events, data are particularly 
lacking for differentiation and migration assays, while prolifer-
ation, network function and behavioral assays in zebrafish have 
broader coverage of compound space. Finally, of the currently 
available assays, none focus on glial endpoints, so there is clear-
ly a need to develop glial-specific assays (see discussion above).
6  How can the field of NAM-based  
approaches to DNT testing develop in the short- 
term versus mid-term / long-term?
Here, examples are given for different types of approaches. The 
examples define knowledge gaps and research needs of areas 
that are not yet ready but have large potential.
6.1 How ready is the pathway concept for  
immediate use?
It is well documented that DNT compounds impair key neuro-
developmental processes leading to diverse pathologies through 
Tab. 5: Examples of signaling pathways and disturbed neurodevelopmental processes involved in diverse  
neurodevelopmental pathologies 
Exposure to compounds that disrupt certain signaling pathways during brain development may impair key neurodevelopmental processes 
resulting in diverse neurodevelopmental pathologies. This table presents a few selected examples of signaling pathway dysfunction.
Abbreviations: AKT, protein kinase B (PKB) signaling pathway; BDNF, brain derived neurotrophic factor; CREB, cAMP responsive  
element binding protein; ESC, embryonic stem cells; NCC, neural crest cells; NPC, neural precursor cells; PSC, pluripotent stem cells; 
TH, thyroid hormone. 
  Exemplary signaling pathways important for normal brain development
  CREB TH BDNF AKT
 Neurodevelopmental  Decreased activity:  Decreased levels:  Decreased levels:  Pathway activation:  
 pathologies associated  involved in deficit of deficit in cognitive impairment of learning human brain 
 with signaling pathway cognitive function  function (AOP 54, 42) and memory overgrowth syndromes 
 dysfunction (AOP 13, 54, 42)  (AOP 12, 13, 54) in humans
 Differentiation of PSC     X 
 into NPC; NPC proliferation    NPC proliferation
 NCC proliferation and X   X 
 migration Proliferation
 Differentiation of ESCs  X     
 towards neurons
 Radial glia migration  X
 Neurite outgrowth X X X X
 Neuronal differentiation    X
 Synaptogenesis X X X 
 Neuronal network  X X  X 
 formation and function
 Glial cell differentiation;   X 
 myelination  Oligodendrocytes,  
   myelination  
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intracellular signaling pathways, including MAPK, PI3K and 
PLCγ1 (Soulé et al., 2006). TrkB-mediated signaling regulates 
gene transcription in the nucleus through the activation of several 
transcription factors that regulate neurite outgrowth, synapto-
genesis, synapse maturation, stabilization and synaptic plasticity 
(Nelson and Alkon, 2015; Nagappan and Lu, 2005). Experimen-
tal evidence shows that loss of BDNF through transgenic models 
or pharmacological manipulation leads to impaired long-term 
potentiation (LTP) (Monteggia et al., 2004) and decreased learn-
ing and memory (Lu et al., 2008). The important role for BDNF 
in LTP and learning and memory is suggested from numerous 
studies in rodents. Hippocampal LTP is impaired in mice lacking 
BDNF in their neurons, and BDNF enhances LTP in the hippo-
campus and visual cortex (reviewed in Mattson, 2008).
In humans, a common single-nucleotide polymorphism in the 
BDNF gene results in poor performance on learning and mem-
ory tasks and contributes to the pathogenesis of depression and 
anxiety disorders (reviewed in Cohen and Greenberg, 2008). 
Similarly, transgenic mice with this mutation display deficits in 
learning and memory tasks as well as anxiety-related behaviors 
(reviewed in Cohen and Greenberg, 2008). BDNF has also been 
shown to play a pivotal role in a variety of learning paradigms in 
a variety of animal models such as mice, monkeys, zebra finch-
es and chicks (reviewed in Tyler et al., 2002). It is suggested 
that BDNF, ERK and CREB play an important role in neuronal 
plasticity through regulation of gene expression to adapt to en-
vironmental changes.
As documented in DNT AOP 138 (AOP-Wiki: Chronic 
binding of antagonist to N-methyl-D-aspartate receptors 
(NMDARs) during brain development induces impairment 
of learning and memory abilities) and AOP 549 (Inhibition 
of Na+/I-symporter (NIS) leads to learning and memory im-
pairment), a reduced level of BDNF has been defined as the 
upstream KE that triggers downstream KEs such as reduced 
presynaptic glutamate release, increased neuronal cell death, 
and aberrant dendritic morphology, leading to decreased syn-
aptogenesis and decreased neuronal network function resulting 
in impairment of learning and memory in children, the adverse 
outcome in these two AOPs.
Experimental support for a relationship between reduced 
BDNF levels and affected downstream KE can be triggered by 
lead exposure as described in detail in the DNT AOP 13. 
TH (thyroid hormone) signaling pathway
The thyroid hormones (TH) triiodothyronine (T3) and thyroxine 
(T4) are essential for brain development, maturation, and func-
tion as they regulate the early key developmental processes such 
as neurogenesis, neuronal migration, proliferation, myelination 
and neuronal and glial differentiation and maturation (de Esco-
bar et al., 2004; Bernal, 2015). Normal human brain develop-
ment and thus cognitive function rely on sufficient TH presence 
during the perinatal period. 
The developing brain depresses neurogenesis, and TH admin-
istration stimulates it. T3 acts through TRα1 nuclear receptor to 
neuronal apoptosis, decreased synaptogenesis, or altered neuro-
nal network formation, have already been identified as KEs in 
the existing DNT AOPs (Table 2A in Bal-Price and Meek, 2017). 
Selected signaling pathways involved in a variety of neurodevel-
opmental processes are described below (Tab. 5).
CREB (cAMP responsive element binding protein)  
signaling pathway
The CREB pathway is crucial in the development of the cen-
tral nervous system (CNS), including neuronal survival, neurite 
outgrowth, precursor proliferation and neuronal differentiation 
(Lonze and Ginty, 2002; Lesiak et al., 2014) during brain devel-
opment. It regulates cell density, neuronal morphology, synaptic 
connectivity (e.g., potentiates transmitter release, promotes den-
drogenesis), neuronal excitability, glutamatergic and GABAer-
gic neurotransmission. 
It also plays an important role in learning and memory forma-
tion through converging BDNF-ERK-CREB signaling cascades 
in brain development, especially amygdala dependent learning 
and neuronal plasticity (Ehrlich and Josselyn, 2016). CREB acts 
as an effector of multiple signaling cascades to transmit signals 
from the synapse to the nucleus, affecting transcription of plas-
ticity-regulated genes. 
A wide range of stimuli can activate CREB signaling in neu-
rons, including hormones, neurotransmitters, growth factors 
and Ca2+, but also stress (Lonze and Ginty, 2002). In addition, 
CREB is a phosphorylation target of AKT, which is activated by 
BDNF and tyrosine kinase B (TrkB) receptors via the phosphati-
dylinositol-3 kinase (PI3K) pathway. Phosphorylation of CREB 
allows it to interact with transcriptional coactivators to promote 
transcription of genes enabling structural and functional plastici-
ty of neurons (Ehrlich and Josselyn, 2016). 
Due to the variety of their functions, CREB as well as BDNF 
and ERK have been linked to a range of psychiatric disorders in-
cluding autism spectrum disorders. The relevance of the CREB 
pathway for neurotoxicity has been demonstrated, showing that 
perturbation of the CREB signaling pathway leads to neurotox-
icity (Schuh et al., 2002; Zuo et al., 2009; Brunelli et al., 2012) 
including in vivo DNT upon exposure to fluoride and arsenic 
(Zhu et al., 2017), lead (Toscano et al., 2002), paraquat+maneb 
(Li et al., 2016) and using human PSC-derived mixed neuronal/
glial cultures (Pistollato et al., 2014).
BDNF (Brain-derived neurotrophic factor) signaling pathway
The neurotrophin BDNF plays an important role during brain 
development. BDNF is critical for the formation of appropriate 
synaptic connections in the brain since it regulates dendritic 
morphogenesis and axon guidance and its growth (reviewed in 
Park and Poo, 2013). Responses of growing axons to extracel-
lular gradients of BDNF trigger activation of the PI3K, MAPK 
and phospholipase C-γ (PLC-γ) (for review see Huang and 
Reichardt, 2003; Huber et al., 2003). 
The biological functions of BDNF are mediated by binding 
to TrkB receptor, which leads to the activation of three major 
8 https://aopwiki.org/aops/13
9 https://aopwiki.org/aops/54
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quent adverse neurodevelopmental outcomes in mammals10), 
a reduced level of TH in the blood results in lower TH levels 
in the brain, which leads to alterations in gene expression and 
subsequent protein levels (e.g., decreased levels of BDNF) that 
are associated with alterations in neuroanatomical structures and 
physiological functions, which ultimately lead to impairment of 
cognitive function (AO). This has been shown for chemicals that 
inhibit NIS (e.g., perchlorate) or TPO (e.g., propylthiouracil, 
methimazole). Experimental support for a relationship between 
decreased TH levels and KEs that lead to this AO is described in 
detail in the AOP-Wiki. Recently the OECD published a scoping 
document where currently available in vitro and ex vivo assays 
for evaluation of disturbance of thyroid functions, including TH 
signaling pathways, are characterized (OECD, 2014a)
AKT signaling pathway
AKT regulates a variety of general cellular processes, including 
cell proliferation and growth, autophagy, apoptosis and migra-
tion. AKT activity is hereby steered by RTK-PI3K-stimulation, 
with RTK-PI3K-AKT further activating the mammalian target 
of rapamycin (mTOR; Hennessy et al., 2005; Yu and Cui, 2016; 
Zheng et al., 2011), glycogen synthase kinase 3β (GSK3β), 
and β-catenin (Manning and Toker, 2017; Fang et al., 2007). 
The pivotal role of this RTK-PI3K-AKT signaling pathway in 
brain development is well established because dysregulation of 
this assembly in either direction leads to several neurodevelop-
mental diseases, such as megalocephaly, microcephaly, autism 
spectrum disorders, intellectual disability, schizophrenia, and 
epilepsy (reviewed in Hevner et al., 2015; Wang et al., 2017). 
On the cellular level, elevation of the PI3K-AKT-mTOR sig-
naling pathway stimulates NPC proliferation, neuronal hyper-
trophy, and excessive dendritic branching, whereas suppression 
has the opposite consequences (Costa-Mattioli and Monteggia 
2013; Huber et al., 2015; Lipton and Sahin, 2014; Zhou and 
Parada, 2012).
In the organism, AKT is represented by three isoforms, 
AKT1, AKT2 and AKT3 in a tissue-specific manner. The effects 
of altered AKT1-3 abundance in mouse brains (Easton et al., 
2005) as well as transgenic modulations of AKT1 and 3 in mice 
(Easton et al., 2005; Tschopp et al., 2005; Tokuda et al., 2011) 
indicate that AKT1 and 3 are the isoforms mainly responsible 
for guidance of neurodevelopmental processes. AKT3 knockout 
mice display a selective reduction in brain size (Easton et al., 
2005; Tschopp et al., 2005), whereas mice with an activating 
AKT3 mutation have larger brains and a thicker corpus callo-
sum. AKT1 deficiency also leads to decreased brain size, how-
ever, by a distinct mechanism: while Akt3 -/- mutants display a 
reduction in both cell size and cell number, Akt1 -/- mice only 
show reduced cell numbers (Easton et al., 2005).
In human fetal brains, AKT3 expression is by far overrepre-
sented compared to the two other isoforms (Wu et al., 2009), 
pointing to a major involvement of AKT3 in human brain de-
velopment. The significance of this RTK-PI3K-AKT pathway 
for human brain development in vivo is demonstrated by the 
increase the commitment of neural stem cells to migrating neu-
roblasts. Neuronal migration in the cerebral cortex, hippocam-
pus and cerebellum is extremely sensitive to TH, and even minor 
deficiencies are associated with migration defects (Berbel et al., 
2001). Among possible mechanisms is the action on the radial 
glia. The radial glia extend long processes to the cerebral wall, 
providing a scaffold that serves for cell migration. Maturation 
of radial glia in the fetal rat brain is delayed in the hippocampus 
of hypothyroid rats. Thyroid hormones may influence neuronal 
migration in the cerebral cortex through regulation of the expres-
sion of the Reln gene in interneurons. 
TH also controls the expression of many genes encoding 
proteins with roles in terminal neuronal and glial differentiation 
(Morte et al., 2010). Among them are cell cycle regulators, cyto-
skeletal proteins, neurotrophins and neurotrophin receptors and 
extracellular matrix proteins. A striking phenotype in the hypo-
thyroid neonatal brain is a reduction in myelination (Adamo et 
al., 1990) as TH is involved in oligodendrocyte differentiation 
(Nygard et al., 2003). After prolonged neonatal hypothyroid-
ism, the number of myelinated axons in adult rats is abnormally 
low, which corresponds with decreased expression of the major 
constituents of myelin (myelin basic protein (MBP), proteolip-
id protein (Plp), 2', 3'-cyclic nucleotide 3'-phosphodiesterase 
(CNPase) and myelin associated glycoprotein (MAG) (Bernal, 
2015). 
In humans, developing brain hypothyroidism based on TH 
transporter mutations that cause a lack of TH uptake through 
the blood-brain-barrier into the developing brain causes severe 
neurodevelopmental deficits as seen in the Allan-Herndon- 
Dudley Syndrome. These patients show delayed myelination 
due to less oligodendrocyte formation or maturation or a com-
bination of both (Tonduti et al., 2013; López-Espíndola et al., 
2014). Hence, neurodevelopmental effects due to disturbance of 
TH homeostasis can be due to either systemic TH disruption, 
i.e., due to thyroid dysfunction or altered TH metabolism, or 
both. These differences in modes-of-action need consideration 
when studying TH disruption in vitro.
With regard to local TH disrupting effects on developing 
brain cells, TH effects on O4+ oligodendrocyte formation and 
maturation was recently studied in human and mouse NPC 
differentiating into three major brain cell types, neurons, oligo-
dendrocytes and astrocytes. While TH stimulates formation and 
maturation of mouse NPC-derived O4+ cells in vitro, TH guides 
only oligodendrocyte maturation in the human in vitro system. 
The suspected TH disruptor BDE-99 disrupted TH-dependent 
O4+ cell maturation only in mouse NPC, while it reduced gener-
ation of human O4+ cells independent of TH signaling in human 
NPC (Dach et al., 2017). This work proposed the “oligodendro-
cyte maturation assay” as a test for distinguishing between hu-
man neural TH disruptors and oligodendrocyte toxicants (Dach 
et al., 2017).
As described in DNT AOPs (AOP 54: Inhibition of Na+/ 
I- symporter (NIS) leads to learning and memory impairment9 
and AOP 42: Inhibition of thyroperoxidase (TPO) and subse-
10 https://aopwiki.org/aops/42
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application, only part of this physiological interaction network 
needs to be described, and the level of detail can be limited 
to essentials. Thus, the ontology is fit for purpose if it covers 
the subnetwork of adverse outcome pathways (AOP) that can 
be triggered by toxicant exposure (Vinken, 2013). An AOP is 
defined as the linear, one-directional route from molecular ini-
tiating event (MIE) triggered by a compound, via a number of 
causally linked KE steps from the molecular, via the cellular 
and tissue to the organism level, leading to a defined adverse 
outcome. The toxicity pathway network can be understood as 
a compilation of all AOPs, including their interrelationships. 
This may include stimulating and repressing interactions and 
feedback information, together describing the pathway from 
compound exposure to adverse effects at the organism level 
(Tonk et al., 2015). From this AOP network it should be pos-
sible to select a limited number of rate-limiting KEs in the 
network that are sufficient to predict all toxicant-induced ad-
verse health effects. These KEs then need to be represented in a 
limited combination of animal-free assays. The challenge then 
remains to develop a computational model which combines the 
outcomes of these assays and translates them into a predictor of 
toxicity. In developmental toxicity, such models are emerging, 
so far describing individual developmental processes and their 
perturbation by chemical exposure (Kleinstreuer et al., 2013; 
Hutson et al., 2017; Leung et al., 2016). Thus, first steps are 
being taken on the way to full coverage of toxicity pathways in 
computational systems toxicology. 
The above ontology-derived selection of in vitro assays can 
be employed in different ways, depending on available knowl-
edge on the chemicals of interest. This information may include 
biological activity, physicochemical properties, structure-activ-
ity relationships of related compounds, and expected use pat-
terns. Case by case, relevant assays can be selected and carried 
out in battery or tiered approaches to optimally and pragmat-
ically collect the necessary information about affected AOPs 
and its consequences for hazard and risk assessment. Such 
flexible approaches can be described in IATA, as formulated 
by OECD (Tollefsen et al., 2014). IATA-based approaches are 
inherently flexible, are designed on the principles of “fit-for-
purpose” and “case by case”, and require scientific justification 
based on all available knowledge. It is therefore paramount that 
the ontology underlying these approaches be comprehensive 
as to monitoring all possible toxicity pathways, and be fine-
tuned to model the human situation. In vitro assays included in 
IATA should ideally be based on human derived cell cultures to 
avoid interspecies differences (Fritsche et al., 2017a). This will 
increase scientific confidence in the reliability of the system 
as a whole as to sufficient coverage of the entire spectrum of 
toxicology.
The validation of such testing strategies for DNT or combi-
nations of assays requires a novel approach. Validation studies 
on the predictivity of individual assays in the past were based 
on limited numbers of compounds, and have shown limited 
relevance for alternative groups of chemicals (Marx-Stoelting 
et al., 2009). In addition, the notion that reductionist in vitro 
assays cannot represent the complexity of the intact organism 
neurodevelopmental effects of mutations overstimulating its 
signaling. These can be grouped into mutations causing over-
stimulation of RTK (Cohen and Kreiborg, 1990; Faivre et al., 
2002; Hevner, 2005; D’Ercole and Ye 2008), PI3K and AKT 
(Flores-Sarnat et al., 2003; Salamon et al., 2006), or AKT down-
stream signaling (Fraser et al., 2004; Li et al., 2002) that are 
responsible for diverse brain overgrowth disorders. These data 
strongly support the notion that compounds interfering with the 
RTK-PI3K-AKT-mTOR signaling cascade by stimulation or 
inhibition will lead to an adverse neurodevelopmental outcome.
Because of the function of AKT in regulation of brain size, 
NPC might be a useful cell method for studying functional ef-
fects of impaired AKT signaling. It was recently shown that the 
AKT signaling machinery is functional in human NPC (Iacon-
elli et al., 2017). In addition, neuronal differentiation models 
might be adequate to study AKT effects on neuronal mass and 
dendrite branching.
Exemplary signaling pathways and disturbed neurodevelop-
mental processes involved in neurodevelopmental pathologies
Based on the in vivo data cited above, a few examples of neu-
rodevelopmental pathologies associated with specific pathway 
dysfunction that are involved in deregulation of certain neuro-
developmental processes are illustrated in Table 5. These neu-
rodevelopmental pathologies are correlated to environmental 
chemical exposures as described in the relevant DNT AOPs. As 
shown, cognitive functional deficits (including impairment of 
learning and memory) in children is the most frequent adverse 
outcome associated with the disturbance of these selected sig-
naling pathways and damaged neurodevelopmental processes. 
Most of these dysregulated neurodevelopmental processes could 
also be studied using the in vitro test methods evaluated in this 
manuscript.
6.2  Towards an ontology-based concept  
of future DNT testing
Individual alternative tests should obviously be characterized 
for their variability, reproducibility and transferability (Hartung 
et al., 2004). In addition, the biological domain of the assay 
and its chemical applicability domain are crucial aspects for 
characterization of the range and limitations of use of each 
assay. These technical characteristics are paramount to allow 
interpretation of results of any assay in any context. Howev-
er, the classical approach of assessing predictive performance 
(predictivity, sensitivity, specificity) on the level of individual 
test systems needs reconsideration in view of innovative ap-
proaches that employ testing strategies involving combinations 
of tests rather than a single individual assay replacing an animal 
study (Piersma et al., 2013; Leist et al., 2014). 
The concept of ontologies provides a basis for transition to a 
biology-based system of animal-free hazard and risk assessment 
(Brinkley et al., 2013). For computational toxicology, ontolo-
gies can be defined as networks of factors that are connected by 
their quantitative relationships. They can, for example, be used 
as a matrix to describe physiology from the molecular, via cel-
lular, tissue and organ to the organism level. For toxicological 
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mation is not adequate to address the regulatory need (problem 
formulation), the IATA will identify data gaps that can be used to 
guide the generation of new data.
It is strongly advised that an IATA should be mechanistically 
informed (Tollefsen et al., 2014; Worth and Patlewicz, 2016; 
OECD 2016a,b), referring to the pathways of toxicity through 
which chemicals trigger the cascade of KE resulting in an ad-
verse outcome. This information can be captured using the 
AOP framework. For some human adverse outcomes (e.g., skin 
sensitization), various mechanistically informed DAs have al-
ready been developed based on AOPs (AOP-informed IATA). 
AOP-informed IATA for skin sensitization incorporates meth-
ods anchored against KE identified in the published AOP in 
conjunction with non-testing approaches ((Q)SAR, read-across) 
(Patlewicz et al., 2014; Fitzpatrick and Patlewicz, 2017; OECD, 
2016b). 
Currently, in the area of DNT, only a few DNT AOPs are 
available. Notably, these differ clearly from adult neurotoxic-
ity AOPs (e.g., Schildknecht et al., 2017), which supports the 
notion that DNT assessment requires very different approaches 
and concepts compared to the evaluation of toxic hazard for 
the adult nervous system. Further development of a sufficient 
number of AOPs that are relevant to DNT will take time, as 
more mechanisms of DNT need to be unraveled. This situation 
should, however, not delay development and implementation of 
a testing strategy such as an IATA. Therefore, it was suggested 
during the recent OECD/EFSA DNT workshop that besides the 
KEs defined in the existing DNT AOPs, the fundamental neuro-
developmental processes critical for normal brain development 
could serve as a basis for developing a battery of test methods 
for DNT testing (Fritsche et al., 2017a). This assumes that ner-
vous system development will be impaired when key biological 
processes are sufficiently disturbed (Lein et al., 2005; Smirnova 
et al., 2014). In other words, the assays anchored to AOP KEs 
and key neurodevelopmental processes will serve to predict 
adverse DNT outcomes. Based on this assumption, readiness of 
in vitro assays anchored to these critical DNT processes (Fig. 1) 
have been evaluated (Tab. 3) to decide which assays are ready 
to be included in IATA. The information presented in Table 3 
suggests that assays permitting evaluation of cell migration, 
proliferation, neurite outgrowth, synaptogenesis and neuronal 
network formation and function are ready to be used for screen-
ing purposes. The acceptable level of uncertainty for screening 
can be higher when compared to other regulatory purposes such 
as hazard or risk assessment. It is advisable that this battery of 
in vitro DNT tests is based on in vitro neuronal/glial models 
originating from human IPSCs in order to be as close as possible 
to human biology.
The above selected in vitro assays are supported by recently 
developed DNT AOPs (Bal-Price and Meek, 2017; Bal-Price 
et al., 2015b) in which impairment of these critical neurodevel-
opmental processes has been identified as late KEs, leading to 
adverse outcome, e.g., learning and memory deficit in children 
(AOP 138; AOP 549). Interestingly enough, these AOPs (Tab. 
2A in Bal-Price and Meek, 2017) are triggered by various MIEs 
and different early KEs, but KEs close to adverse outcome such 
has also hampered acceptance of alternative methods (Piersma 
et al., 2014). In contrast, the animal study protocols, which 
were introduced half a century ago as models for human hazard 
and risk assessment, have been accepted without validation, 
but their introduction was based on general agreement in the 
scientific arena that these were the best possible models for the 
human situation. Likewise, one could contemplate introducing 
ontology-based testing strategies without the validation proce-
dure as regards predictivity that is currently common practice 
for individual alternative assays. Given that ontology-based 
testing strategies are designed to cover the entire network of 
toxicological mechanisms, and moreover can be fine-tuned to 
human physiology, these strategies should be considered in-
herently superior to animal testing procedures, based on their 
sufficient coverage of the human biology that is targeted by 
toxicant exposures. Of course, these approaches are still in their 
infancy and need considerable further development. However, 
as proofs of principle emerge for defined aspects of the toxico-
logical spectrum, these approaches merit further development 
in the interest of improved chemical hazard and risk assess-
ment, using animal-free methods fine-tuned to the species of 
interest, which is the human.
6.3  Towards the development of Integrated 
Approaches to Testing and Assessment (IATA) 
IATA are structured strategies that integrate and weight different 
types of data, based on the “fit-for-purpose” principle to address 
questions of hazard, safety or risk assessment within a specific 
regulatory decision context (Tollefsen et al., 2014). They incor-
porate multiple sources of information from different levels of 
biological organization obtained by a variety of methods ((Q)
SAR, read-across, in chemico, in vitro but also human data, ex 
vivo, in vivo, etc. or omics technologies (e.g., proteomics, tox-
icogenomics, metabolomics)) (Tollefsen et al., 2014; OECD, 
2016a) to assess whether the existing information is sufficient to 
address the purpose-specific regulatory decision. 
To begin, problem formulation should be clearly defined 
as it will influence the IATA construction in terms of data re-
quirements, types of testing (e.g., in vitro, in chemico, in vivo), 
non-testing methods ((Q)SAR, read-across), data integration 
approaches and acceptable level of uncertainty (e.g., screening 
and prioritization versus hazard or risk assessment). Taking 
into consideration the huge gap of knowledge (only 19 known 
human DNT compounds identified so far; Evans et al., 2016), 
the most urgent issue is to develop IATA for chemical screening 
and prioritization purposes (the problem formulation) that could 
serve as a promising tool, permitting initial identification of 
substances with DNT potential among thousands of non-tested 
chemicals to which humans are exposed. Having such data that 
sufficiently covers the biology of the system (especially as to 
toxicity pathways) will improve confidence that IATA is useful 
in identification of DNT compounds.
IATA construction should be initiated by gathering all existing 
information (human data, in vivo, in vitro, non-testing data) on 
a chemical that is evaluated through weight of evidence assess-
ment based on expert judgment. However, if the existing infor-
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Since there are only few identified DNT compounds, the out-
lined IATA (Fig. 6, 7) is proposed for screening and prioritiza-
tion of chemicals of unknown DNT effects. The first stage in that 
IATA workflow aims to gather existing information on chemical 
form and structure, the relevant route of entry, and whether it 
passes, e.g., the placenta or blood-brain barrier (Schultz et al., 
2015). If there is not enough existing information, then the IA-
TA refers to the scenario where new data must be generated to 
take a decision. The purpose of this IATA is priority setting, 
i.e., is the compound of DNT concern or not? This is a problem 
formulation relevant of course for chemicals regulated under 
the US Toxic Substance Control Act (TSCA) for which no data 
is available. However, it is also relevant in very data-rich sce-
narios such as pesticides, since it has been concluded that the 
triggers for requiring DNT studies in the pesticide regulations 
are not sensitive enough and do not have adequate biological 
as neuronal differentiation, synaptogenesis or neuronal network 
formation and function are shared common KEs (CKEs) in sev-
eral AOPs. Therefore, the assays that permit in vitro evaluation 
of these common KEs are relevant candidates for inclusion in an 
IATA battery of DNT tests. The existing DNT AOPs (Bal-Price 
and Meek, 2017; Bal-Price et al., 2015b) provide a mechanistic 
understanding of the linked KEs and adverse outcomes, thus 
increasing scientific confidence in the relevance of the select-
ed in vitro test methods and providing a mechanistic/biological 
context for IATA development (Tollefsen et al., 2014). Further 
development of AOPs relevant to DNT is strongly encouraged, 
as AOP-informed IATA will play a pivotal role in shifting em-
phasis from traditional DNT toxicity testing that is entirely based 
on animals to more tailored, hypothesis-based and predictive 
approaches taking into account existing mechanistic information 
at various levels of biological organization. 
Fig. 6: An IATA designed for DNT screening/prioritization purposes
The IATA was designed for screening/prioritization purposes and was coupled to a decision tree for the DNT regulatory decision  
making. The IATA integrates multiple sources of existing information (human data, in vivo, in vitro and non-testing data) and guides the 
targeted generation of new data when required. If further testing is required, the battery of in vitro DNT tests that permit evaluations  
of key neurodevelopmental processes and KE identified in the relevant AOPs, combined with non-testing methods (e.g., QSARs and 
read-across) are proposed to be included in the DNT IATA for chemical screening and prioritization. Abbreviations: ADME, absorption, 
distribution, metabolism and excretion; Cmpd, compound; DNT, developmental neurotoxicity; HBRV, health-based reference value;  
MoE, margin of exposure; QIVIVE, quantitative in vitro in vivo extrapolation; QSAR, quantitative structure activity relationship. 
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case, further hazard and risk characterization or exposure data 
are required.
An IATA for DNT hazard identification and characterization 
is also envisaged (Fig. 7). Since DNT effects can also be mediat-
ed by endocrine modes of action (e.g., AOP 54) and assays and 
models are already in place to detect effects at least for estro-
gen, androgen and steroidogenesis modalities and partly for the 
thyroid (McCarthy, 2008; Bernal, 2015), it would be relevant 
to first establish whether such modes of action are involved. 
If this is not the case, then the IATA for hazard identification 
and characterization of non-ED mediated DNT effects should 
be applied. In this case, if further information is needed for 
regulatory decision making, a tiered testing strategy should be 
applied, where the in vitro DNT battery would be the first tests 
to be conducted. If further data are needed, then higher tiers 
would include testing in alternative species (e.g., zebrafish) and, 
coverage in terms of toxicity pathways, since very different and 
even unique pathways operate during the development of the 
nervous system (Fritsche et al., 2017b). Consequently, DNT 
data are often not available, and therefore screening and priority 
setting is also warranted. In Figure 6 an outline for a decision 
tree is proposed. Obviously, if no effects are detected, then there 
is no immediate concern with regard to DNT. If DNT effects 
are detected in in vitro assay(s), then there might be a need to 
extrapolate the in vitro concentrations to in vivo concentrations 
(QIVIVE) (Yoon et al., 2012); as a default the lowest effect 
level should be chosen. Depending on the regulatory context, 
other data may be available and a health-based reference value 
(HBRV) may already exist (as for pesticides) or not. In both 
scenarios, a decision can be made on comparing the effect levels 
to a risk-management-defined acceptable safety margin and the 
compound can be deemed of low or high priority. In the latter 
Fig. 7: Incorporation of potential endocrine effects into an IATA for DNT hazard identification/characterization 
Before applying the IATA, it would be important to determine whether any DNT hazard could potentially be due to an endocrine mediated 
mode of action (MoA). Assays and models are in place (or under development) for regulatory purposes (for estrogen, androgen, steroid and 
thyroid (EATS) modalities). For the regulatory decision making, any further characterization of DNT effects by the proposed IATA should 
be integrated with the EATS information. Abbreviations: ADME, absorption, distribution, metabolism and excretion; AOP, adverse outcome 
pathway; Cmpd, compound; DNT, developmental toxicity; EATS, estrogen, androgen, steroid and thyroid modalities; HBRV, health-based 
reference value; IATA, integrated approach to testing and assessment; QSAR, quantitative structure activity relationship.
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if necessary, ultimately rodent models. In such a scenario, it is 
obviously crucial that there is confidence in the adequacy of the 
biological coverage of the first (lower) tier tests. The advantage 
of such an approach is that the data collected in the lower tiers 
could probably inform on the relevant in vivo testing and thus 
a targeted design focusing only on producing required informa-
tion by applying certain selected endpoints would be adequate 
– thus avoiding the full-scale, costly TG 426 study. The regula-
tory decision has to integrate all other relevant data and if DNT 
effects occur this could result in proposals for classification and 
labelling and/or establishment of HBRVs. 
For regulatory decisions, if the compound has no effect in the 
lower tier tests, there would most likely not be a concern if the 
compound is within the applicability domain of the assay/QSAR. 
If DNT effect(s) are observed, the lowest effect concentration 
from the most sensitive assay should be extrapolated into in vivo 
concentrations by quantitative in vitro to in vivo extrapolation 
(QIVIVE). For this, test methods and algorithms for prediction 
of toxicokinetic properties (not covered in this report) would be 
essential (e.g., Wetmore, 2015; Meek and Lipscomb, 2015). The 
required data do not necessarily need to be derived from animals 
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testing strategy, it is proposed to first test in the battery of in 
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zebrafish assays. If further in vivo testing is required (rodent 
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and cost-effective test than the TG 426 or TG 443 could be con-
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reference doses (HBRD), the data derived from the IATA should 
be integrated with other effect data. 
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